MAR 2 8 2002

PTO/SB/08A (10-01)

Under the Paperwork Reduction Act of control number.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

5, no persons are required to respond to a collection of information unless it contains a valid OMB

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

Complete if Known					
Application Number 09/703.753					
Filing Date	November 1, 2000				
	Robert E. Dudley				
	1617				
	S. Jiang				
Attorney Docket Number	01736349				

	U.S. PATENT DOCUMENTS						
Examiner Initials*	1.7.	Document Number  Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
5 9KY	1	us-4496556	01/29/1985	Orentreich			
	2	us-4695465	09/22/1987	Kigasawa, et al.			
	3	us-4863970	09/05/1989	Patel, et al.			
	4	us-4946870		Partain, et al.			
	5	us-5053227		Chiang, et al.	-		
	6	us-5059603		Rubin	, .		
	7	us-5152997		Ebert, et al.			
	8	us-5256652		El-Rashidy			
	9	us-5324521		Gertner, et al.			
	10	us-5332577	07/26/1994	Gertner, et al.			
	11	us-5340586	08/23/1994	Pike, et al.			
	12	us-5346901	09/13/1994	Bell, et al.			
	13	us-5362497	11/08/1994	Yamada, et al.			
	14	us-5413794	05/09/1995	Suzuki, et al.			
	15	us-5460820	10/24/1995	Ebert, et al.			
	16	US-5550107	08/27/1996	Labrie			
	_17	US- 5648350		De Lignieres			
	18	US-5719197		Kanios, et al.			
	19	us-5723114	03/03/1998	Thornfeldt, et al.	·		
7991	20	US-5744162	04/28/1998	Okabe, et al.			

, ,	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code 3 - Number 4 - Kind Code 5 (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵			
_					,				

Examiner Signature		Date Considered	4	125/02
	- 7			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbol Total Indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-01) Approved for use through 10/31/2002. OMB 0651-0031

S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1985 no persons are required to respond to a collection of information unless it contains a valid OMB

& TRADE

Complete if Known

**Application Number** 09/703.753 Filing Date November 1, 2000 First Named Inventor Robert E. Dudlev

Art Unit 1617

**Examiner Name** S. Jiang Attorney Docket Number 01736349

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of 21

Substitute for form 1449A/PTO

	U.S. PATENT DOCUMENTS						
Examiner Initials*		Document Number  Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
291/	21	us-5785991	07/28/1998	Burkoth, et al.			
	22	US-5788983	08/04/1998	Chien, et al.			
$\perp$	23	US-5855905	01/05/1999	Oettel, et al.			
	24	us-5877216	03/02/1999	Place, et al.			
	25	us-5932227	08/03/1999	Higo, et al.			
	26	us-5955455	09/21/1999	Labrie			
	27	us-6010716	01/04/2000	Saunal, et al.			
	28	us-6036977	03/14/2000	Drizen, et al.			
<u> </u>	29	us-6037346	03/14/2000	Doherty, et al.			
1	30	us-6075028	06/13/2000	Graham			
	31	us-6077841		Sui, et al.			
	32	us-6087362	07/11/2000	El-Rashidy			
	33	us-6087368		Macor, et al.			
	34	us-6103765		Neal			
	35	us-6124461	09/26/2000	Shoemaker			
	36	us-6127363		Doherty, et al.			
$\perp$	37	us-6139873		Hughes, Jr., et al.			
	38	us-6156753	12/05/2000	Doherty, et al.			
And	/39	us-6238284 B1	05/29/2001	Dittgen, et al.			
240	40	us-6248363 B1	06/19/2001	Patel, et al.			

		FORE	IGN PATENT D	OCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (Funown)	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
	_					
	-					
*						
						$\vdash$

Examiner Signature	SAY	Date Considered	4/25/02

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
red to respond to a collection of information under the collection of information. quired to respond to a collection of information unless it contains a valid OMB Under the Paperwork Reduction Act of

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of 21

Complete if Known				
Application Number	09/703.753			
Filing Date	November 1, 2000			
	Robert E. Dudlev			
Art Unit	1617			
Examiner Name	S. Jiang			
Attorney Docket Number	01736349			

				U.S. PAT	ENT DOCUMENTS		
Examiner Initials*		Document Number  Number-Kind Code <sup>2</sup> (if kn	own,	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
69H)	41	US-6251436 I	B11	06/26/2001	Drizen, et al.		
0	42	us-6266560 I	B1	07/24/2001	Zhang, et al.	·	
	43	US-6267985 I	B1	07/31/2001	Chen, et al.		
	44	US-6277884 I	<u> 31</u>	08/21/2001	de Tejada		
	45	US-6294192 I	<u> 31</u>	09/25/2001	Patel, et al.		
	46		31	09/25/2001	Place, et al.		
	47	US-6299900 F	31	10/09/2001	Reed, et al.		
	48	US-6306841 F	<b>B</b> 1	10/23/2001	Place, et al.		
	49	US-6323242 F	31	11/27/2001	Mueller		
	50	US-6331543 F	31	12/18/2001	Garvey, et al.		
	51	US-010018073 A	۸ĪI	08/30/2001	Dittgen, et al.		
	52	US-010023261 A	41	09/20/2001	Ryoo, et al.		
	53	us-010033870 A	41	10/25/2001	Luo, et al.		
	54	US-010036483	$\Delta 1$	11/01/2001	Luo, et al.		
	/ 55	US-010051166 A	41	12/13/2001	Luo, et al.		
500	56	US-010051656 A	$\mathbf{M}$	12/13/2001	Place, et al.		
		US-					
		US-					
		US-					
		US-					

	FOREIGN PATENT DOCUMENTS							
Examiner	Cite	Foreign Patent D	ocument	D. b. (1 - 4) D - 4 -	Name of Patentee or	Pages, Columns, Lines,		
	No.1	Country Code 3 -Number 4 -Kind	Code <sup>5</sup> (Kiknown)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	TB	
59N	57	wo 92/15289	A1	09/17/1992	Mantelle			
10	58	WO 93/25168	✓ A1	12/23/1993	Heiber, et al.		Г	
	59	wo 94/21230	A1	09/29/1994	Elias, et al.			
	60	wo 94/28902	Al	12/22/1994	Ellis, et al.			
	61	wo_96/16644	A1	06/06/1996	Campbell, et al.		Π	
	62	wo 96/16657	A1		Cambell, et al.			
	63	wo 96/27372	A1	09/12/1996	Allen			
	64	wo 96/36339	A2	11/21/1996	Mantzoros		Г	
and/	65	wo 97/03985	A1	02/06/1997	Daugan, et al.			
290	66	wo 97/24148	A1	07/10/1997	Chen, et al.			

Examiner Date Signature Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP Applicants under diation designation number (optional). \*See Kinds Codes of USP10 Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. \*§ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*§ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*§ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*§ Applicant is to place a check mark here if English language Translation is attached.

MAR 2 8 2002 25

TRADE

PTO/SB/08A (10-01) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are equired to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 21

Complete if Known			
Application Number	09/703.753		
Filing Date	November 1, 2000		
	Robert E. Dudlev		
Art Unit	1617		
Examiner Name	S. Jiang		
Attorney Docket Number	01736349		

		U.S. PATE	NT DOCUMENTS	
Examiner Initials*	Document Number Number - Kind Code 2 (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	US-			
	US₊			
	US-	(1)		
	US-			·
	US-	<del></del>		
	US-			
	US-			
	US		-	
	ÚS-			
	us-			
$\overline{}$	US-			

			FORE	IGN PATENT D	OCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Docume  Country Code 3 -Number 4 -Kind Code 5		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Te
504	67	wo 97/43989	A1	11/27/1997	Portman, et al.		
	68	WO 98/34621	A1		Rako		
	69	wo 99/24041	A1		Mak. et al.		
	70	wo 99/66870	Al		Fotinos		
	71	wo 00/45795	A2	08/10/2000			
	72	wo 00/76522	A1	12/21/2000	Rosario-Jansen, et al.		
	73	wo 01/52823	_A2	A = 10 / 10 A A 4	Kanios		
	74	wo 01/76608	A1	10/18/2001	Lipp, et al.		
	75	EP 0196769	A2	10/08/1996	Chien, et al.		
54U	76	EP 0483105	B2	04/29/1992	Cleary		

	Examiner Signature	Sal	Date Considered 4/25/57
--	-----------------------	-----	-------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995 to persons a valid OMB
control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 21

Complete if Known					
Application Number	09/703.753				
Filing Date	November 1, 2000				
	Robert E. Dudley				
Art Unit	1617				
Examiner Name	S. Jiang				
Attorney Docket Number	01736349				

		U.S. PATE	NT DOCUMENTS	
Examiner Initials*	 Document Number Number - Kind Code <sup>2</sup> (if known	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	US-			
	US-		<u> </u>	
	US-	0		
	US-			
	US-			
	US-			
	 US-			
	US-	. *		
	US-			
	US-			
	US <sub>2</sub>			
	ÚS.			
	US-			
	US-			
	US-			

		FOR	EIGN PATENT D	OCUMENTS	7	
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code 3 - Number 4 - Kind Code 5 (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	7.
GWY	77	EP 0491076 A1	06/24/1992			Г
- /	78	EP 0513832 A1	11/19/1992	Parab		
SEC	79	EP 0581587 A2		Kobayashi, et al.		
		· · · · · · · · · · · · · · · · · · ·				
					<del></del>	<u> </u>
					<del></del>	ļ
					· · · · · · · · · · · · · · · · · · ·	┢
					· · · · · · · · · · · · · · · · · · ·	┢
						<del>                                     </del>

Examiner Signature Date Considered Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw life through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

十

PTO/SB/08BR(1001). 2002

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Control number. TRADE

PTO/SB/08BR(1001). 2002

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Control number. TRADE

PTO/SB/08BR(1001). 2002

Substitute fo	r form 1449B/PTO		Complete if Known			
		NOOL OOLIDE	Application Number	09/703.753		
INFOR	KIVIATION L	DISCLOSURE	Filing Date	November 1, 2000		
STATE	EMENT BY	APPLICANT	First Named Inventor	Robert E. Dudlev		
DIAILMENT DI AFFEIDAN			Group Art Unit	1617		
	(use as many she	ets as necessary)	Examiner Name	S. Jiang		
Shoot	6	21	Attorney Docket Number	01726340		

		NON DATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Ţ <sup>2</sup>
90	80	RINGHAM, ET AL., "Dose Proportionality and Systemic Bioavailability of a Testosterone Topical Gel in Hypogonadal Men," Unimed Pharmaceuticals (October 31, 2000).	
	81	LONGSTRETH, ET AL., "Transdermal Testosterone Pharmacokinetics Remain Unchanged With Prolonged Treatment," Unimed Pharmaceuticals (October 31, 2000).	
•	82	KAUFMAN, "Efficacy and Safety of a New, Topical Testosterone Gel (T-gel) For Male Hormonal Supplementation," International Journal of Impotence Research," Vol. 12 (Supplement 3), p. S75 (B9) (September 2000).	
	83	JORDAN, "Allergy and Topical Irritation Associated With Transdermal Testosterone Administration: A Comparison of Scrotal and Nonscrotal Transdermal Systems," American Journal of Contact Dermatitis. Vol. 8 (No. 2). pp. 108-113 (June 1997).	
	84	GOUCHIE, ET AL., "The Relationship Between Testosterone Levels and Cognitive Ability Patterns," Psychoneuroendocrinology, Vol. 16 (No. 4), pp. 323-334 (1991).	
	85	DOBS, ET AL., "Pharmacokinetics, Efficacy, and Safety of a Permeation-Enhanced Testosterone Transdermal System in Comparison with Bi-Weekly Injections of Testosterone Enanthate for the Treatment of Hypogonadal Men," The Journal Of Clinical Endocrinology And Metabolism, Vol. 84 (No. 10), pp. 3469-3478 (1999).	
•		PERSKY, ET AL., "Plasma Testosterone Level and Sexual Behavior of Couples," Archives of Sexual Behavior, Vol. 7 (No. 3), pp. 157-173 (May 1978).	
	87	AHMED, ET AL., "Transdermal Testosterone Therapy in the Treatment of Male Hypogonadism," Journal Of Clinical Endocrinology And Metabolism, Vol. 66 (No. 3), pp. 546-551 (March 1988).	
	88	BALS-PRATSCH, ET AL., "Transdermal Testosterone Substitution Therapy for Male Hypogonadism," The Lancet, Vol. 2 (No. 8513), pp. 943-46 (October 25, 1986).	
	89	PLYMATE, ET AL., "Circadian Variation in Testosterone, Sex Hormone-Binding Globulin and Calculated Non-Sex Hormone-Binding Globulin Bound Testosterone in Healthy Young and Elderly Men," Journal of Andrology, Vol. 10 (No. 5), pp. 366-371 (September-October 1989).	
99		CUNNINGHAM, ET AL., "Testosterone Replacement with Transdermal Therapeutic Systems - Physiological Serum Testosterone and Elevated Dihydrotestosterone Levels," JAMA, Vol. 261 (No. 17), pp. 2525-2530 (May 5, 1989).	

Examiner	<i>590</i>	Date 420
Signature		Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid CMB control number.

E.

						~~2
Substitute fo	or form 1449B/PTO		TRADEMA	Со	Inplete if Known-C!! CENTED 10	ha
INIEO	DRACTION I	DIE	CLOSURE	Application Number	09/703.753	JU/
INFO	ZIVIA LICIN I	DISC	PLOSUKE	Filing Date	November 1, 2000	İ
STAT	EMENT BY	/ AF	PLICANT	First Named Inventor	Robert E. Dudley	
				Group Art Unit	1617	İ
·····	(use as many she	ets as	necessary)	Examiner Name	S. Jiang	
Sheet	7	of	21	Attorney Docket Number	01736349	•

	_	NON PATENT LITERATURE DOCUMENTS	_
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	7
79 <b>(</b> )	91	TENOVER, ET AL., "Age-Related Alterations in the Circadian Rhythms of Pulsatile Luteinizing Hormone and Testosterone Secretion in Healthy Men," Journal of Gerontology, Vol. 43 (No. 6), pp. M163-169 (November 1988).	
	92	CONWAY, ET AL., "Randomized Clinical Trial of Testosterone Replacement Therapy in Hypogonadal Men," International Journal Of Andrology, Vol. 11 (No. 4), pp. 247-264 (August 1988).	
·	93	PLACE, ET AL., "Transdermal Delivery of Testosterone with Testoderm to Provide Normal Circadian Pattern of Testosterone," Annals New York Academy of Sciences, Vol. 618, pp. 441-449 (1991).	
	94_	BHASIN, ET AL., "A Biodegradable Testosterone Microcapsule Formulation Provides Uniform Eugonadal Levels of Testosterone for 10-11 Weeks in Hypogonadal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 74 (No. 1). pp. 75-83 (January 1992).	
	95	ARVER, ET AL., "Improvement of Sexual Function in Testosterone Deficient Men Treated for 1 Year with a Permeation Enhanced Testosterone Transdermal System," Journal Of Urology, Vol. 155 (No. 5), pp. 1604-1608 (May 1996).	
		LIAO, "Androgen Action: Molecular Mechanism and Medical Application," J. Formos Med. Assoc., Vol. 93 (No. 9), pp. 741-751 (September 1994).	
	97	CARLSTROM, ET AL., "Relationship Between Serum Testosterone and Sex Hormone-Binding Globulin in Adult Men with Intact or Absent Gonadal Function," International Journal Of Andrology (Vol. 13), pp. 67-73 (1990).	-
	98	de LIGNIERES, ET AL., "Treatment of Male Hypogonadism by Topical Administration of Androgens," pp. 273-283 (1980).	
	99	DAVIDSON, ET AL., "Hormonal Changes and Sexual Function in Aging Men,"  Journal Of Clinical Endocrinology And Metabolism, Vol. 57 (No. 1), pp. 71-77 (1983).	
	l	VERMEULEN, ET AL., "Long-Term Transdermal Dihydrotestosterone Therapy: Effects on Pituitary Gonadal Axis and Plasma Lipoproteins," Maturitas, Vol. 7, pp. 281-287 (1985).	
7	I	MORRISON, "Androgens in the Elderly: Will Androgen Replacement Therapy Improve Mood, Cognition, and Quality of Life in Aging Men and Women," Psychopharmacology Bulletin, Vol. 33 (No. 2), pp. 293-296 (1997).	

Examiner	$\leq gg$	Date Why or	
Signature	// 4)	Considered T/V 3/90	
			_

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B Approved for use through 10/31/2002 OMB 0651-0031

I.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE)
and to respond to a collection of Information unless it contains a valid OMB

Under the Paperwork Reduction Act of 1999 The pe

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) of Sheet

Complete if Known 09/703.753 Application Number Filing Date November 1 Robert E. Dudley **First Named Inventor** Group Art Unit 1617 **Examiner Name** S. Jiang Attorney Docket Number | 01736349

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*		Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>		
9		102	JAFFE, ET AL., "Effect of 5-Alpha-Reductase Inhibition on Sex-Hormone-Binding Globulin in Elderly Men", Horm. Res., Vol. 41, pp. 215-217 (1994).			
		103	MORLEY, ET AL., "Androgen Deficiency in Aging Men: Role of Testosterone Replacement Therapy," J. Lab. Clin. Med., Vol. 135 (No. 5), pp. 370-378 (May 2000).			
		104	MARIN, ET AL., "Androgen Treatment of Middle-Aged, Obese Men: Effects on Metabolism, Muscle and Adipose Tissues," European Journal of Medicine, Vol. 1 (No. 6). pp. 329-336 (October 1992).			
		105	WANG, ET AL., "Pharmacokinetics of Transdermal Testosterone Gel in Hypogonadal Men: Application of Gel at One Site Versus Four Sites: A General Clinical Research Center Study," The Journal Of Endocrinology And Metabolism, Vol. 85 (No. 3), pp. 964-969 (March 2000).			
		106	KUHN, ET AL., "Percutaneous Androgen Treatment for Male Hypogonadism. Compared Efficacy of Testosterone and Dihydrotestosterone: Study of 40 Observations," Endocrinologie, Vol. 14 (No. 11), pp. 1031-1036 (1986) (English Translation)			
		107	HANDELSMAN, ET AL., "Pharmacokinetics and Pharmacodynamics of Testosterone Pellets in Man," Journal Of Clinical Endocrinology And Metabolism, Vol. 70 (No. 1), pp. 216-222 (1990).			
		108	STUENKEL, ET AL., "Sublingual Administration of Testosterone-Hydroxypropyl-b-Cyclodextrin Inclusion Complex Simulates Episodic Androgen Release in Hypogonadal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 72 (No.5), pp. 1054-1059 (May 1991).			
	:	109	BHASIN, "Clinical Review 34 - Androgen Treatment of Hypogonadal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 74 (No. 6), pp. 1221-1225 (June 1992).			
		110	SALEHIAN, ET AL., "Pharmacokinetics, Bioefficacy, and Safety of Sublingual Testosterone Cyclodextrin in Hypogonadal Men: Comparison to Testosterone Enanthate - A Clinical Research Center Study," Journal Of Clinical Endocrinology And Metabolism, Vol. 80 (No. 12), pp. 3567-3575 (1995).			
			MEIKLE, ET AL., "Pharmacokinetics and Metabolism of a Permeation-Enhanced Testosterone Transdermal System in Hypogonadal Men: Influence of Application Site - A Clinical Research Center Study," Journal Of Clinical Endocrinology And Metabolism, Vol. 81 (No. 5), pp. 1832-1840 (May 1996).			
5	ag		WANG, ET AL., "Testosterone Replacement Therapy Improves Mood in Hypogonadal Men - A Clinical Research Center Study," Journal Of Clinical Endocrinology And Metabolism, Vol. 81 (No. 10), pp. 3578-3583 (1996).			

Examiner	$\sim$ ad	Date	- C.	1200 -
Signature	9/ 7	Considered	$\mathcal{F}$	103/-
				-17

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031

O.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE of to respond to a collection of information unless it contains a valid OMB

Under the Paperwork Reduction Act of 199 control-number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) ----9- --- --|-of-|

Complete if Known 09/703.753 Application Number November 1, 2000 Filing Date Robert E. Dudley First Named Inventor Group Art Unit 1617 S. Jiang **Examiner Name** .Attorney\_Docket\_Number . 01736349

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
59,J	113	WANG, ET AL., "Sublingual Testosterone Replacement Improves Muscle Mass and Strength, Decreases Bone Resorption, and Increases Bone Formation Markers in Hypogonadal Men - A Clinical Research Center Study," Journal Of Clinical Endocrinology And Metabolism, Vol. 81 (No. 10), pp. 3654-3662 (1996).	
	114	McCLELLAN, ET Al., "Transdermal Testosterone," Drugs, Vol. 55 (No. 2), pp. 253-258 (February 1998).	
	115	BHASIN, ET AL., "Therapeutic Perspective - Issues in Testosterone Replacement in Older Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 83 (No. 10), pp. 3435-3448 (1998).	
	116	BEHRE, ET AL., "Intramuscular Injection of Testosterone Undecanoate for the Treatment of Male Hypogonadism: Phase I Studies," European Journal Of Endocrinology, Vol. 140. pp. 414-419 (1999).	
	117	BEHRE, ET AL., "Long-Term Substitution Therapy of Hypogonadal Men with Transscrotal Testosterone Over 7-10 Years," Clinical Endocrinology, Vol. 50, pp. 629-635 (1999).	
	118	PARKER, ET AL., "Experience with Transdermal Testosterone Replacement Therapy for Hypogonadal Men," Clinical Endocrinology, Vol. 50, pp. 57-62 (1999).	
		SNYDER, ET AL., "Effect of Testosterone Treatment on Bone Mineral Density in Men Over 65 Years of Age," The Journal Of Clinical Endocrinology And Metabolism, Vol.84 (No. 6), pp. 1966-1972 (1999).	
		WANG, ET AL., "Comparative Pharmacokinetics of Three Doses of Percutaneous Dihydrotestosterone Gel in Healthy Elderly Men - A Clinical Research Center Study," Journal Of Clinical Endocrinology And Metabolism, Vol. 83 (No. 8). pp. 2749-2757 (August 1998).	
		LEIFKE, ET AL., "Effects of Testosterone Replacement Therapy on Cortical and Trabecular Bone Mineral Density, Vertebral Body Area and Paraspinal Muscle Area in Hypogonadal Men," European Journal of Endocrinology, Vol. 138. pp. 51-58 (1998).	
59Y		BEHRE, ET AL., "Long-Term Effect of Testosterone Therapy on Bone Mineral Density in Hypogonadal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 82 (No. 8), pp. 2386-2390 (1997).	

Examiner	$\leq 20$	Date	4/25/02
Signature		Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, control number.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE to respond to a collection of information unless it contains a valid/OMB

Substitute for form 1449B/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Complete if Known Q 09/703.753 **Application Number** November 1, 2000 € Filing Date Robert E. Dudley First Named Inventor Group Art Unit 1617 **Examiner Name** S. Jiang Attorney Docket Number 01736349

(use as many sheets as necessary) 10 of Sheet

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
39	123	DAMASSA, ET AL., "Sex Hormone-Binding Globulin and Male Sexual Development," Neuroscience And Biobehavioral Reviews, Vol. 19 (No. 2), pp. 165-175 (1995).			
	124	MORLEY, ET AL., "Longitudinal Changes in Testosterone, Luteinizing Hormone, and Follicle-Stimulating Hormone in Healthy Older Men," Metabolism, Vol. 46 (No. 4), pp. 410-413 (April 1997).			
		CUNNINGHAM, ET AL., "Plasma Sex Hormone-Binding Globulin Levels Decrease During the Second Decade of Life Irrespective of Pubertal Status," Journal Of Clinical Endocrinology And Metabolism, Vol. 58 (No. 5), pp. 915-918 (1984).	-		
	126	LEWIS, ET AL., "Serum 5a-Dihydrotestosterone and Testosterone Changes with Age in Man," ACTA Endocrinologica, Vol. 82, pp. 444-448 (1976).			
	127	HARDY, ET AL, "Endocrine Assessment of Impotence - Pitfalls of Measuring Serum Testosterone Without Sex-Hormone-Binding Globulin," Postgrad Medical Journal. Vol. 70. pp. 836-837 (1994).			
	128	DAVIDSON, ET AL., "Hormonal Replacement and Sexuality in Men," Clinics In Endocrinology And Metabolism, Vol. 11 (No. 3), pp. 599-623 (November 1982).			
	129	MANTZOROS, ET AL., "Contribution of Dihydrotestosterone to Male Sexual Behavior," British Medical Journal, Vol. 310, pp 1289-1291 (May 20, 1995).			
	130	MOORADIAN, ET AL., "Biological Actions of Androgens," Endocrine Reviews, Vol. 8 (No. 1), pp 1-28 (1987).			
	131	CUNNINGHAM, ET AL., "Testosterone Replacement Therapy and Sleep-Related Erections in Hypogonadal Men," Journal Of Clinical Endocrinology and Metabolism, Vol. 70 (No. 3), pp. 792-797 (1990).			
	132	SKAKKEBAEK, ET AL., "Androgen Replacement with Oral Testosterone Undecanoate in Hypogonadal Men: A Double Blind Controlled Study," Clinical Endocrinology, Vol. 14, pp. 49-61 (1981).			
5901	/	de LIGNIERES, "Transdermal Dihydrotestosterone Treatment of Andropause,"			
	133	Annals Of Medicine, Vol. 25, pp. 235-241 (1993).			

Examiner	<0 Y	Date 4/x/57
Signature		Considered (/ )

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Approved for use through 10/31/2002. OMB 0651-0031.

Approved for use through 10/31/2002.

Approved for use Under the Paperwork Reduction Act of 1995, no persons are required control number.

Substitute fo	or form 1449B/PTO		TRADE	Co	mplete if Known	3/2
INIEO	IAOITA MAC	DICC	LOSURE	Application Number	09/703.753	F
INFO	VIVIA HON	DISC	LOSUKE	Filing Date	November 1, 2000	
STAT	EMENT B	Y AP	PLICANT	First Named Inventor	Robert E. Dudley	1,0
• • • • • • • • • • • • • • • • • • • •				Group Art Unit	1617	. 6
	(use as many sh	eets as r	ecessary)	Examiner Name	S. Jiang	4
Sheet	11	of	21	Attorney Docket Number	01736349	1

		NON PATENT LITERATURE DOCUMENTS	,
Examiner Initials*			T²
99	134	CHEMANA, ET AL., "Percutaneous Absorption of 5a-dihydrotestosterone in Man II. Percutaneous Administration of 5a-dihydrotestosterone in Hypogonadal Men with Idiopathic Haemochromatosis: Clinical, Metabolic and Hormonal Effectiveness," International Journal Of Andrology, Vol. 5, pp. 595-606 (1982).	
	135	McCLURE, ET AL., "Hypogonadal Impotence Treated by Transdermal Testosterone," Urology, Vol. XXXVII (No. 3), pp. 224-228 (March 1991).	
	136	GOOREN, "Androgen Levels and Sex Functions in Testosterone-Treated Hypogonada Men," Archives Of Sexual Behavior, Vol. 16 (No. 6), pp. 463-473 (1987).	1
	137	TSITOURAS, "Effects of Age on Testicular Function," Endocrinology And Metabolism Clinics, Vol. 16 (No. 4), pp.1045-1059 (December 1987).	
	138	ANDERSON, ET AL., "The Effects of Exogenous Testosterone on Sexuality and Mood of Normal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 75 (No. 6). pp.1503-1507 (1992).	
<u>.</u>	139	KNUSSMANN, ET AL., "Relations Between Sex Hormone Levels and Sexual Behavior in Men," Archives Of Sexual Behavior, Vol. 15 (No.5), pp. 429-5 (1986).	
	140	BANCROFT, "Endocrinology of Sexual Function," Clinics In Obstetrics And Gynecology, Vol. 7 (No. 2), pp. 253-281 (August 1980).	
	141	BAGATELL, ET AL., "Effects of Endogenous Testosterone and Estradiol on Sexual Behavior in Normal Young Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 78 (No. 3), pp. 711-716 (1994).	
		WEINBAUER, ET AL., "Pharmacokinetics and Pharmacodynamics of Testosterone Enanthate and Dihyrotestosterone Enanthate in Non-Human Primates," ACTA Endocrinologica (COPENH), Vol. 122 (No. 4), pp. 432-442 (1990).	
	143	"Sexual Dysfunction in the Male - Sexual Arousal Disorder," The Merck Manual, Sixteenth Edition, Ch. 139, pp. 1575-1576 (1992).	
- 599)		JOCKENHOVEL, ET AL., "Pharmacokinetics and Pharmacodynamics of Subcutaneous Testosterone Implants in Hypogonadal Men," Clinical Endocrinology, Vol. 45, pp. 61-71 (1996).	

Examiner Signature	594	Date Considered	4/25/02

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are control number.

PTO/SB/08B (10-01)

Approved forme through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ired to respond to a collection of information unless it contains a valid OMB

Complete if Known Substitute for form 1449B/PTO **Application Number** 09/703.753 INFORMATION DISCLOSURE Filing Date November 1. STATEMENT BY APPLICANT Robert E. Dudlev First Named Inventor Group Art Unit (use as many sheets as necessary) S. Jiang Examiner Name 12 Sheet Attorney Docket Number 01736349

		NON PATENT LITERATURE DOCUMENTS	_
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	1
	145	BEHRE, ET AL., "Testosterone Buciclate (20 Aet-1) in Hypogonadal Men: Pharmacokinetics and Pharmacodynamics of the New Long-Acting Androgen Ester," Journal Of Endocrinology And Metabolism," Vol. 75 (No. 5), pp. 1204-1210 (1992).	
	146	SCHURMEYER, ET AL., "Comparative Pharmacokinetics of Testosterone Enanthate and Testosterone Cyclohexanecarboxylate as Assessed by Serum and Salivary Testosterone Levels in Normal Men," International Journal of Andrology, Vol. 7, pp. 181-187 (1984).	
	147	MAZER, ET AL., "Enhanced Transdermal Delivery of Testosterone: A New Physiological Approach for Androgen Replacement in Hypogonadal Men," Journal of Controlled Release, Vol. 19, pp. 347-361 (1992).	
	148	COFRANCESCO, Jr., ET AL., "Transdermal Testosterone Delivery Systems," The Endocrinologist, Vol. 6 (No. 3), pp. 207-213 (1996).	
	149	BROCKS, ET AL., "Pharmacokinetics of Testosterone in Hypogonadal Men After Transdermal Delivery: Influence of Dose," Journal of Clinical Pharmacology. Vol. 36, pp. 732-739 (1996).	
	150	ARVER, ET AL., "Long-Term Efficacy and Safety of a Permeation-Enhanced Testosterone Transdermal System in Hypogonadal Men." Clinical Endocrinology. Vol. 47, pp. 727-737 (1997).	
	151	MEIKLE, ET AL., "Androderm: A Permeation Enhanced Non-Scrotal Testosterone Transdermal System for the Treatment of Male Hypogonadism," Pharmacology, Biology, and Clinical Applications of Androgens, Vol. 43, pp. 449-457 (1996 Wiley-Liss, Inc.).	
·		BALS-PRATSCH, ET AL., "Substitution Therapy of Hypogonadal Men with Transdermal Testosterone Over One Year," ACTA Endocrinologica (COPENH), Vol. 118, pp. 7-13 (1988)	
<u> </u>	153	CAREY, ET AL., "Transdermal Testosterone Treatment of Hypogonadal Men," The Journal of Urology, Vol. 140, pp. 76-79, (July 1988).	
SOL	154	CUNNINGHAM, ET AL., "Testosterone Transdermal Delivery System," Pharmacology, Biology, and Clinical Applications of Androgens, Vol. 42, pp. 437-447 (1996 Wiley-Liss, Inc).	
	155	Product Information Testoderm-T-TS, Physicians' Desk Reference; Alza pp.	

Examiner Signature Date Considered 4/25/07		
	SA	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

01736349

Approved for use through 10/31/2002. OMB 0651-0031

S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ed to respond to a collection of information unless it contains availed OMB Under the Paperwork Reduction Act of 1995 the persons are recontrol number. Complete if Known

Substitute for form 1449B/PTO 09/703.753 **Application Number** INFORMATION DISCLOSURE Filing Date November 1, 2000 STATEMENT BY APPLICANT Robert E. Dudley **First Named Inventor** Group Art Unit 1617 (use as many sheets as necessary) **Examiner Name** S. Jiano 13 Sheet of Attorney Docket Number

f			
		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
59()	156	YU, ET AL., "Testosterone Pharmacokinetics after Application of an Investigational Transdermal System in Hypogonadal Men," Journal of Clinical Pharmacology, Vol. 37, pp. 1139-1145 (1997).	
	ĺ	YU, ET AL., "Transdermal Testosterone Administration in Hypogonadal Men: Comparison of Pharmacokinetics at Different Sites of Application and at the First and Fifth Days of Application," Journal of Clinical Pharmacology, Vol. 37, pp. 1129-1138 (1997).	
	158	WALTERS, "Penetration Enhancers and Their Use in Transdermal Therapeutic Systems," pp. 202-227 (1990).	
	159	GENNARO, "Remington: The Science and Practice of Pharmacy, 20th Edition," Chapter 44, pp. 842-843 (2000).	
	160	JARKANDER-ROLFF, ET AL., "Transdermal Application of A Testosterone Gel - A Pharmacokinetic Study."	
	161	TIRASSA, ET AL., "High-Dose Anabolic Androgenic Steroids Modulate Concentrations of Nerve Growth Factor and Expression of its Low Affinity Receptor (p75-NGFr) in Male Rat Brain," Journal of Neuroscience Research. Vol. 47 (No. 2). pp. 198-207 (January 15, 1997).	
	162	VELDHUIS, ET AL., "Muting of Androgen Negative Feedback Unveils Impoverished Gonadotropin-Releasing Hormone/Luteinizing Hormone Secretory Reactivity in Healthy Older Men," The Journal of Clinical Endocrinology & Metabolism. Vol. 86 (No. 2). pp. 529-535. (2001)	
	163	MILLER, ET AL., "Androgen Deficiency in Women with Hypopituitarism," The Journal of Clinical Endocrinology & Metabolism, Vol. 86 (No.2), pp. 561-567 (2001).	
	164	KAO, ET AL., "Skin Absorption and Cutaneous First Pass Metabolism of Topical Steroids: in vitro Studies with Mouse Skin in Organ Culture," Journal of Pharmacology and Experimental Therapeutics, Vol. 241 (No. 2), pp. 482-487 (May 1987).	
		FINDLAY, ET AL., "Treatment of Primary Hypogonadism in Men by the Transdermal Administration of Testosterone," Journal Of Clinical Endocrinology And Metabolism, Vol. 68 (No. 2), pp. 369-373 (February 1989).	
39		ERNESTI, ET AL., "Absorption and Metabolism of Topically Applied Testosterone in an Organotypic Skin Culture," Skin Pharmacology, Vol. 5 (No. 3). pp. 146-153 (1992).	

Examiner	200	Date	1/1/20
Signature		Considered	4//03/00

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act o control number.

PTO/SB/08B (10-01)
Approved for through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE and to respond to a collection of information unless it contains a valid OMB

Complete if Known

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Application Number 09/703.753
Filing Date November 1, 2000
First Named Inventor Robert E. Dudley
Group Art Unit 1617
Examiner Name S. Jiang
Attorney Docket Number 01736349

Sheet 14 of 21

			_
		NON PATENT LITERATURE DOCUMENTS	3
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
49	167	CHOI, ET AL., "Transdermal Dihydrotestosterone Therapy and its Effects on Patients with Microphallus," Journal Of Urology, Vol. 150 (No. 2) (Part 2), pp. 657-660 (August 1993).	
	168	Testosterone, Chapters 1, 6-16 (1999).	
	169	TSAI, ET AL., "Metabolic Approaches to Enhance Transdermal Drug Delivery. 1. Effect of Lipid Synthesis Inhibitors." Journal of Pharmaceutical Sciences, Vol. 85 (No. 6), pp. 643-648 (June 1996).	
	170	MEIKLE, ET AL., "Familial Effects on Plasma Sex-Steroid Content in Man: Testosterone, Estradiol and Sex-Hormone-Binding Globulin," Metabolism. Vol. 31 (No. 1). pp. 6-9 (January 1982).	
	,	SHANBHAG, ET AL., "The Temperature Dependence of the Binding of 5 Alpha-Dihydrotestosterone, Testosterone and Estradiol to the Sex Hormone Globulin (SHBG) of Human Plasma," J. Steroid Biochem., Vol. 24 (No. 2), pp. 549-555 (February 1986).	
	172	BELGOROSKY, ET AL., "Changes in Serum Sex Hormone-Binding Globulin and in Serum Non-Sex Hormone-Binding Globulin-Bound Testosterone During Prepuberty in Boys," J. Steroid Biochem., Vol. 27 (Nos. 1-3), pp. 291-295 (1987).	
	173	KORENMAN, ET Al., "Androgen Therapy of Hypogonadal Men with Transscrotal Testosterone Systems," American Journal Of Medicine, Vol. 83 (No. 3), pp. 471-478 (September 1987).	
	174	MITCHELL, ET Al., "Age Related Changes in the Pituitary-Testicular Axis in Normal Men; Lower Serum Testosterone Results from Decreased Bioactive LH Drive," Clinical Endocrinology (OXF), Vol. 42 (No. 5). pp. 501-507 (May 1995).	
		NANKIN, ET AL., "Decreased Bioavailable Testosterone In Aging Normal and Impotent Men,"  Journal Of Clinical Endocrinology And Metabolism, Vol. 63 (No. 6), pp. 1418-1420 (December 1986).	
		TENOVER, ET AL., "The Effects of Aging in Normal Men on Bioavailable Testosterone and Luteinizing Hormone Secretion: Response to Clomiphene Citrate," Journal Of Clinical Endocrinology And Metabolism, Vol. 65 (No. 6), pp. 1118-1126 (December 1987).	
S9()	/	WINTERS, ET AL., "The Gonadotropin-Suppressive Activity of Androgen is Increased in Elderly Men," Metabolism, Vol. 33 (No. 11), pp. 1052-1059 (November 1984).	

	The second secon		
Examiner		Date	
Signature		Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual citation.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
D.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE and to respond to a collection of information unless it contains a valid OMB

Under the Paperwork Reduction Act of 1913 no persons are reduction number.

Substitute fo	r form 1449B/PTO		TRADE	Complete if Known		
INEOE	MATION	DIS	CLOSURE	Application Number	09/703,753	
				Filing Date	November 1, 2000	
STATI	EMENT B	Y AI	PPLICANT	First Named Inventor	Robert E. Dudlev	
				Group Art Unit	1617	
	(use as many st	neets as	necessary)	Examiner Name	S. Jiang	
Sheet	15	of	21 ::	Attorney Docket Number	01736349	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>39</i> (4)	178	MEIKLE, ET AL., "Enhanced Transdermal Delivery of Testosterone Across Nonscrotal Skin Produces Physiological Concentrations of Testosterone and Its Metabolites in Hypogonadal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 74 (No. 3), pp. 623-628 (March 1992).	
	179	WINTERS, ET AL., "Serum LH Concentrations in Hypogonadal Men During Transdermal Testosterone Replacement Through Scrotal Skin: Further Evidence That Ageing Enhances Testosterone Negative Feedback. The Testoderm Study Group," Clinical Endocrinology (OXF), Vol. 47 (No. 3), pp. 317-322 (September 1997).	
		BOYLE, ET AL., "Serum Testosterone Measurements," American Journal Of Clinical Pathology, Vol. 81 (No. 6), pp. 754-761 (June 1984).	
	181	HOLOWNIA, ET AL., "A Clinical Evaluation of A Direct Radioimmunoassay of Testosterone," Clinical Chimica Acta, Vol. 214 (No. 1), pp. 31-43 (January 31, 1993).	
		BELGOROSKY, ET AL., "Progressive Decrease in Serum Sex Hormone-Binding Globulin from Infancy to Late Prepuberty in Boys," Journal Of Clinical Endocrinology And Metabolism, Vol. 63 (No. 2), pp. 510-512 (August 1986).	
	183	VALERO-POLITI, ET AL., "Daily Rhythmic and Non-Rhythmic Variations of Follitropin, Lutropin, Testosterone, and Sex-Hormone-Binding Globulin in Men," Eur. J. Clin. Chem. Clin. Biochem Vol. 34 (No. 6). pp. 455-462 (June 1996).	
	184	VALERO-POLITI, ET AL., "Annual Rhythmic Variations of Follitropin, Lutropin, Testosterone and Sex-Hormone-Binding Globulin in Men," Clinica Chimica Acta, Vol. 271 (No. 1), pp. 57-71 (March 9, 1998).	
	185	LONGCOPE, ET AL., "Androgens, Estrogens, and Sex Hormone-Binding Globulin in Middle-Aged Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 71 (No. 6), pp. 1442-1446 (December 1990).	
		BELGOROSKY, ET AL., "Dynamics of SHBG Response to Testosterone. Implications Upon the Immediate Biological Effect of Sex Hormones," J. Steroid Biochem., Vol. 18 (No. 6), pp. 783-787 (June 1983).	
	i	LEWIS, ET AL., "Proceedings: Age-Related Changes in Serum Saplha-dihydrotestosterone and Testosterone in Normal Men," Journal Of Endocrinology, Vol. 67 (No. 2), pg. 15P (November 1975).	
59()		PIRKE, ET AL., "Age Related Changes and Interrelationships Between Plasma Testosterone, Oestradiol and Testosterone-Binding Globulin in Normal Adult Males," ACTA Endocrinologica (COPENH), Vol. 74 (No. 4), pp. 792-800 (December 1973).	

Examiner	$\bigcirc Q_i \bigcirc \bigvee$	Date	0/10-7-
Signature	Say	Considered	4/10/00

<sup>\*</sup>EXAMINER: Initial if reference considered, whether of not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Approved for use through 10/31/2002. OMB 0651-0034

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF:COMMERCE puired to respond to a collection of information unless it contains a valid OMB Under the Paperwork Reduction Act of control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known 09/703,753 **Application Number** November 1, 2000 Filing Date **First Named Inventor** Robert E. Dudley Group Art Unit 1617 S. Jiano Examiner Name Attorney Docket Number 01736349

(use as many sheets as necessary) 16 Sheet

Initials\*

NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner Cite item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published MASTERS, ET AL., "Investigation of Sex-Hormone Binding Globulin Interference in Direct Radioimmunoassays for Testosterone and Estradiol," Clinical Chemistry, Vol. 35 (No. 6), pp. 979-984 (June 1989). WANG, ET AL., "Salivary Testosterone in Men: Further Evidence of a Direct Correlation with Free Serum Testosterone," Journal Of Clinical Endocrinology And Metabolism, Vol. 53 (No. 5), pp. 190 1021-1024 (November 1981). ZMUDA, ET AL., "Exercise Increases Serum Testosterone and Sex Hormone-Binding Globulin Levels in Older Men," Metabolism, Vol. 45 (No. 8), pp. 935-939 (August 1996) GAIDANO, ET AL., "Dynamics of the Binding Capacity of Plasma Sex Hormone Binding Globulin (SHBG) for Testosterone and Dihydrotestosterone During Puberty," Clinical Chimica Acta, Vol. 100 (No. 2), pp. 91-97 (January 15, 1980). Definition of Isopropyl Myristate (5103), The Merck Index - An Encyclopedia of 193 Chemicals, Drugs, and Biologicals, Eleventh Edition, p. 821 (1989) GENNARO, ET AL., Remington's Pharmaceutical Sciences, Eighteenth Edition, 194 pp. 1305, 1314-1315 (1990). LANGTRY, ET AL., "Sildenafil - A Review of its Use in Erectile Dysfunction," 195 Drugs, Vol. 57 (No. 6), pp. 967-989 (1999). MORELAND, ET AL., "Sildenafil, A Novel Inhibitor of Phosphodiesterase Type 5 In Human 196 Corpus Cavernosum Smooth Muscle Cells," Life Sciences, Vol. 62 (No. 20) pp. PL309-318 (1998) FAHRNER, ET AL., "Effects of Endurance Exercise on Free Testosterone Concentration and the Binding Affinity of Sex Hormone Binding Globulin (SHBG)," International Journal Of Sports Medicine, 197 Vol. 19 (No. 1). pp. 12-15 (January 1998). [Abstract] BARTSCH, "Interrelationships Between Sex Hormone-Binding Globulin and Testosterone, 5 alpha-Dihydrotestosterone and Oestradiol-17 beta in Blood of 198 Normal Men, "Maturitas, Vol. 2 (No. 2), pp. 109-118 (July 1980). [Abstract] WANG, ET AL., "Effects of Transdermal Testosterone Gel on Bone Turnover Markers and Bone Mineral Density in Hypogonadal Men," Clinical

Examiner	COO	Date	4/2010
Signature	<u> </u>	Considered	1100100

Endocrinology, Vol. 54, pp. 1-13 (2001).

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE equired to respond to a collection of information unless it contains a valid OMB Under the Paperwork Reduction Ac control number.

TRADE Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

17 of Sheet

Complete if Known					
Application Number	09/703.753				
Filing Date	November 1, 2000				
First Named Inventor	Robert E. Dudley				
Group Art Unit	1617				
Examiner Name	S. Jiang				
Attorney Docket Number	01736349				

		NON PATENT LITERATURE DOCUMENTS	_
Examiner Cite Initials* No.		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
99	200	GOOREN, "A Ten-Year Safety Study of the Oral Androgen Testosterone Undecanoate," J. Androl., Vol. 15 (No. 3), pp. 212-215 (May-June 1994). [Abstract]	
	201	MAZER, "New Clinical Applications of Transdermal Testosterone Delivery in Men and Women," J. Controlled Release, Vol. 65 (No. 1-2), pp. 303-315 (March 1, 2000). [Abstract]	
	202	1TOH, ET AL., "The Assessment of Bioavailable Androgen Levels from the Serum Free Testosterone Level, "Nippon Naibunpi Gakkai Zasshi, Vol. 67 (No. 1), pp. 23-32 (January 20, 1991). [Abstract]	
	203	Male Hormone Patch Approved, Nupharm, http://www.nupharm.com/malehorm.htm.	
	204	"SmithKline Beecham's New 5 mg Androderm Testosterone Transdermal System Now Available," International Association of Physicians in AIDS Care, http://www.iapac.org/clinmgt/compnews/sb061297.html (June 12, 1997).	
	205	"Impotence Treatments," Impotence World Association, http://www.impotenceworld.org/treatment.htm (2000).	
	206	"Andro Gel," Netrition, http://www.netrition.com/andro_gel_page.html (1997-1998).	
	207	"Cellegy Pharmaceuticals Market Opportunities," CELLEGY PHARMACEUTICALS, INC., http://www.cellegy.com/corp/market.html (1997).	
	208	"Prospectus - Cellegy Pharmaceuticals, Inc.," OPPENHEIMER & CO., pp. 1-4, 21-28 (1997).	
	209	The Testosterone Source, http://www.testosteronesource.com (1998).	
59Y		BONNEY, "Hormone Replacement Therapy for Men," American Clinical Laboratory, http://iscpubs.com/pubs/acl/acl1-197.html—(November/December1997).	

Examiner	500	Date	Wasto
Signature	A	Considered	7/20/00

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE equired to respond to a collection of information unless it contains a valid OMB MAR 2 8 2002 W Under the Paperwork Reduction Ad control number.

Substitute fo	or form 1449B/PTO	- CO	TRADEMARKS	Complete if Known		
INIEOE	IAOLT A BRI		CLOSURE	Application Number	09/703.753	
HALOE	NIVIA I I ON	DIS	PLOSURE	Filing Date	November 1, 2000	
STATI	EMENT B'	Y AF	PLICANT	First Named Inventor	Robert E. Dudley	
				Group Art Unit	1617	
	(use as many sh	eets as	necessary)	Examiner Name	S. Jiang	
Sheet	18	of	21	Attorney Docket Number	01736349	

- "		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	211	Andropausal, Los Gatos Longevity Institute, <a href="http://www.antiaging.com/andropause.html">http://www.antiaging.com/andropause.html</a> (1998).	
	212	TestoCreme - A Natural Transdermal Testosterone Replacement Therapy,	
99X)	213	WANG, ET AL., "Pharmacokinetics Of Transdermal Testosterone Gel in Hypogonada Men," ENDO '98 SUBMISSION PROGRAM, 1998N ABSTRACT FORM.	1
		SWERDLOFF, ETAL., "Long Term Pharmacokinetics of Transdermal Testosterone Gel Versus Testosterone Patch in Hypogonadal Men," 2347 Male Reproductive Poster Session, Board 578 (June 22, 2000).	
	215	WANG, ET AL., "Effects of Transdermal Testosterone Gel on Bone Turnover Markers and Bone Mineral Density in Hypogonadal Men," 2348 Male Reproductive Poster Session, Board 579 (June 22, 2000).	
	216	WANG, ET AL, "Transdermal Testosterone Gel Improves Sexual Function, Mood, Muscle Strength, and Body Composition Parameters in Hypogonadal Men," Basic Science: Reproduction-Gonadal Control (Male), Male Reproduction Oral Session, No. 1360 (June 24, 2000).	
		"Unimed Pharmaceuticals' Androgel Shows Solid Promise for Men," Fertility Industry News, wwwINGHD:com (August 19, 1998).	
5 <b>9</b> 0	218	RIGGS, "Unimed Begins Pivotal Clinical Trial For Innovative Testosterone Gel," Unimed News Release, pp. 1-2 (March 31, 1997).	
		Androgel-1% (testosterone gel) CIII.; www.Androgel.com, pp. 1-2.	
S9Y	220	VERGEL, "Anabolic Steroids: A Practical Guide," CRIA Update, Vol. 7 (No. 3) (Summer 1998).	
		MOONEY, "Frequencey of Administration - Testosterone & Nandrolone," Vol. 1 (No4); www.medibolies:com-(Downloaded-10/8/98);	

Examiner	$CO\sim$	Date //	
4	999	Date /	126/67 -
Signature		Considered ${\mathcal T}$	100100
		والمسترق المناوي بالمناولات والمستروب والمستروب	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English tanguage Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)
Approved for through 10/31/2002. OMB 0651-0031
Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute fo	r form 1449B/PTO		Carried Stranger	Co	omplete if Known	=======================================	
INEOE	MATION	Diec	LOSURE	Application Number	09/703.753	$\odot$	Ľ.
INFOR	KIVIATION	DISC	LOSUKE	Filing Date	November 1, 200	0==	
STATI	EMENT BY	Y AP	PLICANT	First Named Inventor	Robert E. Dudley	7.7	dc ©
•		• • • • • • • • • • • • • • • • • • • •	· LIOAIII	Group Art Unit	1617		
	(use as many sho	eets as i	necessary)	Examiner Name	S. Jiang	LEI	7 (
Sheet	19	of	21	Attorney Docket Number	01736349		2

	-		_
		NON PATENT LITERATURE DOCUMENTS	3
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
<i>59</i>	22/2	Anabolic Steroids, Project Inform, Anabolic Steroids Quick Sheet (December 1997).	
My	223	"Anabolic Steroid Boosts Weight," GMHC Treatment Issues, Vol. 10, No. 9 (September 1996).	
	224	Anabolic Steroids, Project Inform Hotline Handout, www.projinf.org. (Downloaded-10/8/98).	
	-225	Anabolic Steroids - A Simple Facts Sheet From The Network, www.network/simple/steroids (Downloaded 10/27/98).	
	-226	USP Drug Information - Anabolic Steroids (Systemic), MayoClinic, -www.mayohealth.org-(Downloaded=10/8/98).	
70.	227	MOONEY, "Anabolic Steroids For AIDS Therapy: Differences Between Analogs," No. 1, www.digiweb.com. (July 1998).	
	<del>22</del> 8	Testocreme - No Shots, No Pills, No Patches, www.testoereme:com (Downloaded-7/10/00).	
ĐÝ	229	"ENDO 99: Testosterone Patch Effective For Diminished Sexual Function in Surgically Menopausal Women," www.pslgroup.com-(June 15, 1999).	
AY		"Data Supports Safety of Estratest For Men," Doctor's Guide, www.pslgroup.eom (March 9, 1998).	_
S	231	"Testosterone's Role in the Female Sex Drive," USA Today News, www.usatoday.com (April 8, 1996).	
		"Alternative to Viagra For Women?," www.mdhealthline.com-(Downloaded	_

Examiner	59N	Date	Chlorita
Signature		Considered	4/10/02

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1997 to persons are required to respond to a collection of information unless it contains, a valid OMB control number.

					Lin	
Substitute fo	r form 1449B/PTO	TRADEMARI	Со	mplete if Known	兰.	
INFO	MATION	DISCLOSURE	Application Number	09/703.753	54	39
			Filing Date	November 1, 2000	Z.	
STAT	EMENT B'	Y APPLICANT	First Named Inventor	Robert E. Dudley	m	, (
			Group Art Unit	1617	ند	н.
		eets as necessary)	Examiner Name	S. Jiang	$\mathcal{L}$	'n
Sheet	20	of 21	_Attorney Docket Number	01736349	0	5

		NON PATENT LITERATURE DOCUMENTS	3
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Ţ.
1911	233	"Never Too Buff," Time Europe, www.time.com, Vol. 155 (No. 16) (April 24, 2000).	
	234	Gefael, Graeme's Testosterone Page, www.voyager.co.nz (5/4-2/00).	
	.235	Estrogel, www.netdoktor.dk/medicin/Fakta/Estrogel (Downloaded 6/26/01).	
	23.6	La Sexualite, L'Androgel, Le Gel Miracle,  www.aci-multimedia.net/feminin/androgel (Downloaded-5/9/01)	
Sanda and a sanda and a sanda and a sanda and a sanda and a sanda and a sanda and a sanda and a sanda and a sa	237	Stehli, et al., Info, Info Androgel,  www.mageos-ifrance.com/nade38/androgel (Downloaded 5/9/01):	
	-238	CHERRIER, ET AL., "T-Gel Study: Cognitive Effects of Exogenous Festosterone Manipulation in Hypogonadal-Men" (6/7/99)	
	e: A	"Bentley Pharmaceuticals Annouces Research and Licensing Agreements For Intranasal Pain Management and Topical Hormone Replacement Therapy," www.bentleypharm.com (downloaded -1/1/7/01).	
make feets a literal	240	"Testosterone Gel May Help Men with Low Sex Drive," WRAL ONLINE, http://www.wral-tv.com/features/healthteam/1997/0814-tgel/ (August 14, 1997).	
		"Testocreme Transdermal Testosterone Is New," Preventive Medicine Clinic Of Monterey, http://www.wellnessmd.com/testo.html.	
	242	"SEPA Testosterone Transdermal Gel Receives Application by FDA," Doctor's Guide Global Edition, http://pslgroup.com/dg/123aa.htm.(January-15,-1997).	
		Press Release - 10/21/99 - MacroChem Awarded U.S. Patent Covering Transdermal Hormone Replacement Incorporating Proprietary SEPA Technology and Hormonally Active Drugs Such as Testosterone, Estradiol and Progesterone, <a href="http://www.mchm.com/press/pr24.asp">http://www.mchm.com/press/pr24.asp</a> (October 21, 1999).	

Examiner	120	Date	1/20/10
Signature	59 Y	Considered	11/05/02

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are regarded to respond to a collection of information unless it contains a valid OMB control number.

Substitute fo	or form 1449B/PTO		FRADEMARIE	Со	mplete if Known	Q P
INEO	IAOLTA BE	DIE	CLOSURE	Application Number	09/703.753	0 3
INFOR	TIVIA I ION	סוט	CLUSUKE	Filing Date	November 1, 2000	1/2
STAT	EMENT B	Υ ΔΙ	PPLICANT	First Named Inventor	Robert E. Dudley	7
• • • • • • • • • • • • • • • • • • •			LIOAN	Group Art Unit	1617	<i>S</i>
	(use as many sh	eets as	necessary)	Examiner Name	S. Jiano	6
Sheet	21	of	21	Attorney Docket Number	01736615	6

_		NON PATENT LITERATURE DOCUMENTS	_
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	١
	244	AndrosteDERM, http://www.gethuge.net/androderm1.htm.	
	245	MANOS, "FDA Approves Gel to Treat Low Testosterone Levels," www.testocreme.com (Downloaded 5/09/01).	
The state of the s	246	"Unimed Pharmaceuticals' Androgel Shows Solid Promise for Men," Fertility Industry News, www.INCIID.com (August 19, 1998).	
30		LACAYO, "Are You Man Enough?," Time Europe, www.Time.com, Vol. 155, No. 16 (April 24, 2000).	
		"MacroChem Accelerates Development of Top For Impotence," www.pslgroup.com (April 10, 1997).	
J94		BRADLEY, "Potential Expanded Indications for Androgen Treatment," The Endocrine Society, No. 166 (ENDO 2000).	
	250	WANG, ET AL., "New Androgen Formulations," The Endocrine Society, No. 167 (ENDO 2000).	
	251	WANG, ET AL., "Transdermal Testosterone Gel Improves Sexual Function, Mood, Muscle Strength, and Body Composition Parameters in Hypogonadal Men," The Endocrine Society, No. 1360 (ENDO 2000).	
	252	WITTERT, ET AL., "Androgen Deficiency in Aging Men," The Endocrine Society, No. 1626 (ENDO 2000).	
		BRILL, ET AL., "Single and Joint Impact of One-Month of Transdermal Testosterone (T) and/or Recombinant Human Growth Hormone (rhGH) Supplementation on Body Composition, Strength, Balance, Function and Muscle IGF-I and Androgen Gene Expression in Healthy Older Men: A Prospective Randomized Double-Blind Crossover," The Endocrine Society, No. 1647 (ENDO 2000).	

		<u> </u>	
Examiner	200	Date	4/10/10
Signature		Considered	TINGUE

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. \( \)

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

Co	omplete if Known		
Application Number	09/703.753		
Filing Date	November 1, 2000		;
First Named Inventor	Robert E. Dudley	Ñ	i
Art Unit	1617	3500	
Examiner Name	S. Jiang	ວັນ	1.1.
Attorney Docket Number	01736349		

			U.S. PAT	ENT DOCUMENTS	<u> </u>
Examiner Initials*		Document Number  Number - Kind Code <sup>2</sup> (if known)	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where C Relevant Passages or Relevant Figures Appear C
591	1	us-4496556	01/29/1985	Orentreich	0,
10	2	us-4695465	09/22/1987	Kigasawa, et al.	\
	3	us-4863970	09/05/1989	Patel, et al.	
	4	us-4946870		Partain, et al.	
	5	us-5053227	10/01/1991	Chiang, et al.	
	6	us-5059603	10/22/1991	Rubin	
	7	us-5152997	10/06/1992	Ebert, et al.	
	8	us-5256652	10/26/1993	El-Rashidy	-
	9	us-5324521	06/28/1994	Gertner, et al.	
	10	us-5332577	07/26/1994	Gertner, et al.	<u> </u>
	-11	us-5340586	08/23/1994	Pike, et al.	
	12	us-5346901	09/13/1994	Bell, et al.	
	13	us-5362497	11/08/1994	Yamada, et al.	
	14	us-5413794	05/09/1995	Suzuki, et al.	ည် 6 -
	15	us-5460820	10/24/1995	Ebert, et al.	16 16
	16	US- 5550107	08/27/1996	Labrie	00 0.
	17	US- 5648350	07/15/1997	De Lignieres	
	<b>⊿18</b>	U\$- 5719197	02/17/1998	Kanios, et al.	
	19	us-5723114	03/03/1998	Thornfeldt, et al.	-
SP)	20	US- 5744162	04/28/1998	Okabe, et al.	

		FORE	IGN PATENT D	OCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures. Appear	T®
					C	
					1	Ŀ
	<u> </u>		· .		) M	17.7
	├		<del></del> -	<del></del>		
	<del> </del>				<b>F</b>	٦
					166	120
					0/	2
	2.5				29	
					Ç	

Examiner Signature	SY	Date Considered	5/21/00
-----------------------	----	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbol Translation is obtained. <sup>6</sup> Applicant is to place a check mark here if English languages. The patent document is obtained by the symbol of the patent document is obtained. English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

21 of Sheet

Complete if Known			
Application Number	09/703.753		
Filing Date	November 1, 2000		
First Named Inventor	Robert E. Dudlev		
Art Unit	1617	_	
Examiner Name	S. Jiang		
Attorney Docket Number	01736349		

			U.S. PAT	ENT DOCUMENTS	
Examiner Initials*	Cite No. 1	Document Number  Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
594 X	21	us-5785991	07/28/1998	Burkoth, et al.	
10	22	US- 5788983	08/04/1998	Chien, et al.	
	23	US-5855905	01/05/1999	Oettel, et al.	
	24	us-5877216	03/02/1999	Place, et al.	
	25	us-5932227	08/03/1999	Higo, et al.	
	26	us-5955455	09/21/1999	Labrie	·
	27	us-6010716	01/04/2000	Saunal, et al.	
	28	us-6036977	03/14/2000	Drizen, et al.	C
	29	us-6037346	03/14/2000	Doherty, et al.	
	30	us-6075028	06/13/2000	Graham	ر ببر
	31	us-6077841	06/20/2000	Sui, et al.	2 2
	32	us-6087362	07/11/2000	El-Rashidy	I loud
	33	us-6087368	07/11/2000	Macor, et al.	3 6
	34	us-6103765	08/15/2000	Neal	80 No
	35	us-6124461	09/26/2000	Shoemaker	9,02
$\Box I$	36	us-6127363	10/03/2000	Doherty, et al.	29
	37	us-6139873	10/31/2000	Hughes, Jr., et al.	8 (
	/38	us-6156753		Doherty, et al.	
-m/	39	us-6238284 B1		Dittgen, et al.	
5991	40	us-6248363 B1	06/19/2001	Patel, et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>5</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ,		
			· · · · · · · · · · · · · · · · · · ·		m	Г		
					우	Г		
					С	P		
					EN	Ì		
	<b> </b>					ļ <u>.</u>		
	-					4		
	$\vdash$		<del></del>		8	200		
					<u> </u>	F		
					8	Т		

Examiner Signature	527	Date Considered	5/21/02

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 21

Complete if Known				
Application Number	09/703.753			
Filing Date	November 1, 2000			
First Named Inventor	Robert E. Dudley			
Art Unit	1617			
Examiner Name	S. Jiang			
Attorney Docket Number	01736349			

				U.S. PAT	ENT DOCUMENTS	
Examiner Initials*	. / .	<u>Document Number</u> Number-Kind Code <sup>2</sup> (if kn	own,	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
591	41		31	06/26/2001	Drizen, et al.	
10	42_		31	<u>07/24/2001</u>	Zhang, et al.	
	43		31	07/31/2001	Chen, et al.	
	44		31	<u>08/21/2001</u>	de Tejada	오 -
	45		31	09/25/2001	Patel, et al.	0 유니
	46		31	<u>09/25/2001</u>	Place, et al.	<u> </u>
	47		31	10/09/2001	Reed, et al.	- I
	48		31	10/23/2001	Place, et al.	D 6
	49		31	11/27/2001	Mueller	<del></del>
	50	US-6331543 E	31	12/18/2001	Garvev, et al.	7,000
	51		11	08/30/2001	Dittgen, et al.	3/290 U
	52	US-010023261 A	11	<u>09/20/2001</u>	Ryoo, et al.	
	53	US-010033870 A	<u>\1</u>	10/25/2001	Luo, et al.	0
	54	US-010036483 A	11	11/01/2001	Luo, et al.	· ·
	<b>/</b> 55	US-010051166 A	11	12/13/2001	Luo, et al.	
SUG	56	US-010051656 A	Ш	12/13/2001	Place, et al.	
V		US-				
		US-	$\perp$			
		US-				
		US-		*		·

		FOR	EIGN PATENT D	OCUMENTS		-
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code 3 - Number 4 - Kind Code 5 (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sub>6</sub>
S24)	57	wo 92/15289 A1	09/17/1992	Mantelle	m	
10	58	WO 93/25168 A1	12/23/1993	Heiber, et al.	王	
	59	wo 94/21230 A1	09/29/1994	Elias, et al.	S S	1
	60	wo 94/28902 A1	12/22/1994	Ellis, et al.	Ž	R
	61	WO 96/16644 A1	06/06/1996	Campbell, et al.		4
	62	wo 96/16657 A1	06/06/1996	Cambell, et al.	70	9
	63	wo_96/27372 A1	09/12/1996	Allen	16	2
	64	wo 96/36339 A2	11/21/1996	Mantzoros	0	00
	65	wo 97/03985 A1	02/06/1997	Daugan, et al.	2	٦
SAY)	66	wo 97/24148 A1	07/10/1997	Chen, et al.	90	

Examiner Signature	SIOV	Date Capaidared	5/2	1/02
Signature		Considered		
	· · · · · · · · · · · · · · · · · · ·			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

KECEIVED

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/PTO **Application Number** 09/703.753 INFORMATION DISCLOSURE Filing Date November 1, 2000 STATEMENT BY APPLICANT First Named Inventor Robert E. Dudley Art Unit 1617 (use as many sheets as necessary) S. Jiang **Examiner Name** Sheet of Attorney Docket Number 01736349

		U.S. PATE	NT DOCUMENTS	<del></del>
Examiner Initials*	Document Number  Number - Kind Code <sup>2</sup> (if known,	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	US-		· · ·	
	US-			C
	US-			
	US-			2 0
	US-			<del>2</del> ~ (
	US-			m
	US-			<del>20 on 1</del>
	US-			စ် ခိ
	US-			
	US-			0/29
	US-			8
	US-			
	US-			
	US-			

	FOR	EIGN PATENT D	OCUMENTS		
Examiner Cite Initials* No.	Foreign Patent Document  Country Code 3 - Number 4 - Kind Code 5 (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵
59/ 67	wo 97/43989 A1	11/27/1997	Portman, et al.		
68	WO 98/34621 A1	08/13/1998	Rako		
69		05/20/1999	Mak, et al.	E	
1 70	wo 99/66870 A1	12/29/1999	Fotinos	구 -	
$+\frac{71}{2}$	WO 00/45795 A2	08/10/2000	Lulla, et al.	$\Omega^{\frac{D}{2}}$	
$\frac{1}{12}$	WO 00/76522 A1	12/21/2000	Rosario-Jansen, et al.	<u> </u>	
$-1\frac{13}{23}$	WO 01/52823 A2	07/26/2001	Kanios	<u> </u>	
1 1/4	wo 01/76608 A1	10/18/2001	Lipp, et al.	72 6	
$\leq a \times 1/2$	EP 0196769 A2 EP 0483105 B2	10/08/1996	Chien, et al.	160	
<del>-7)1/0</del>	EP 0483105 B2	<u> </u>	Cleary	00/2	-
Evenine			1	2	᠆;
Examiner Signature	29		Date Considered	>/2/82	Ч

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

21 5 Sheet of

Complete if Known					
Application Number	09/703.753				
Filing Date	November 1, 2000				
First Named Inventor	Robert E. Dudley				
Art Unit	1617				
Examiner Name	S. Jiang				
Attorney Docket Number	01736349				

			U.S. PATE	NT DOCUMENTS	
Examiner Initials*	Cite No. 1	Document Number  Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-	····		rigures Appear
		US-		· · · · · · · · · · · · · · · · · · ·	
		US-			[Tri
		US-			우
		US-			OA
		US-			<u> </u>
		US-			<b>—</b> ,
		US-			70 G
		US-			
		US-			79. 79. 79. 79. 79.
		US-			0/2
		US-		·	0/2900
		US-			6
		US-			
		US-		-	

		FOF	REIGN PATENT D	OCUMENTS	
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code 3 - Number 4 - Kind Code 5 (if known	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
581	77	EP 0491076 A	06/24/1992	Patel, et al.	<u> </u>
70	78		1 11/19/1992		AH C
Sat	79	EP 0581587 A	02/02/1994	Kobayashi, et al.	R R
· V					
_			<b>.</b>		<del>D</del> 6
			<del></del>		<del>6</del> 2 <
		<del></del>			2 8 h
					/29
	<u> </u>				8

Examiner Date Signature Considered-

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicants unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449B/PTO **Application Number** 09/703.753 INFORMATION DISCLOSURE Filing Date November 1, 2000 STATEMENT BY APPLICANT First Named Inventor Robert E. Dudley Group Art Unit 1617 S. Jiang (use as many sheets as necessary) Examiner Name of Attorney Docket Number 01736349 Sheet

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
59	80	RINGHAM, ET AL., "Dose Proportionality and Systemic Bioavailability of a Testosterone Topical Gel in Hypogonadal Men," Unimed Pharmaceuticals (October 31, 2000).	10
	81	LONGSTRETH, ET AL., "Transdermal Testosterone Pharmacokinetics Remain Unchanged With Prolonged Treatment," Unimed Pharmaceuticals (October 31, 2000).	SEOU OFIN
	82	KAUFMAN, "Efficacy and Safety of a New, Topical Testosterone Gel (T-gel) For Male Hormonal Supplementation," International Journal of Impotence Research," Vol. 12 (Supplement 3), p. S75 (B9) (September 2000).	=
	83	JORDAN, "Allergy and Topical Irritation Associated With Transdermal Testosterone Administration: A Comparison of Scrotal and Nonscrotal Transdermal Systems," American Journal of Contact Dermatitis, Vol. 8 (No. 2), pp. 108-113 (June 1997).	
	84	GOUCHIE, ET AL., "The Relationship Between Testosterone Levels and Cognitive Ability Patterns," Psychoneuroendocrinology, Vol. 16 (No. 4), pp. 323-334 (1991).	
	85	DOBS, ET AL., "Pharmacokinetics, Efficacy, and Safety of a Permeation-Enhanced Testosterone Transdermal System in Comparison with Bi-Weekly Injections of Testosterone Enanthate for the Treatment of Hypogonadal Men," The Journal Of Clinical Endocrinology And Metabolism, Vol. 84 (No. 10), pp. 3469-3478 (1999).	0
- J.	 86	PERSKY, ET AL., "Plasma Testosterone Level and Sexual Behavior of Couples," Archives of Sexual Behavior, Vol. 7 (No. 3), pp. 157-173 (May 1978).	- N - P
	87	AHMED, ET AL., "Transdermal Testosterone Therapy in the Treatment of Male Hypogonadism," Journal Of Clinical Endocrinology And Metabolism, Vol. 66 (No. 3), pp. 546-551 (March 1988).	CU CEIVI EI I 1000/F400
	88	BALS-PRATSCH, ET AL., "Transdermal Testosterone Substitution Therapy for Male Hypogonadism," The Lancet, Vol. 2 (No. 8513), pp. 943-46 (October 25, 1986).	200
		PLYMATE, ET AL., "Circadian Variation in Testosterone, Sex Hormone-Binding Globulin and Calculated Non-Sex Hormone-Binding Globulin Bound Testosterone in Healthy Young and Elderly Men," Journal of Andrology, Vol. 10 (No. 5), pp. 366-371 (September-October 1989).	
Say		CUNNINGHAM, ET AL., "Testosterone Replacement with Transdermal Therapeutic Systems - Physiological Serum Testosterone and Elevated Dihydrotestosterone Levels," JAMA, Vol. 261 (No. 17), pp. 2525-2530 (May 5, 1989).	

Examiner Signature	Say	Date Considered	5/21/02
Signature		r Considerear	

+

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE				Complete if Known		
				Application Number	09/703.753	
				Filing Date	November 1, 2000	
STAT	FMFNT R	Υ ΔΡΙ	PLICANT	First Named Inventor	Robert E. Dudley	
STATEMENT BY APPLICANT				Group Art Unit	1617	
	(use as many sh	neets as n	ecessary)	Examiner Name	S. Jiang	
Sheet	7	of	21	Attorney Docket Number	01736349	

			NON PATENT LITERATURE DOCUMENTS	
	Examiner Ci Initials* No		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
59			TENOVER, ET AL., "Age-Related Alterations in the Circadian Rhythms of Pulsatile Luteinizing Hormone and Testosterone Secretion in Healthy Men," Journal of Gerontology, Vol. 43 (No. 6), pp. M163-169 (November 1988).	
		92	CONWAY, ET AL., "Randomized Clinical Trial of Testosterone Replacement Therapy in Hypogonadal Men," International Journal Of Andrology, Vol. 11 (No. 4), pp. 247-264 (August 1988).	
		93	PLACE, ET AL., "Transdermal Delivery of Testosterone with Testoderm to Provide Normal Circadian Pattern of Testosterone," Annals New York Academy of Sciences, Vol. 618, pp. 441-449 (1991).	
		94	BHASIN, ET AL., "A Biodegradable Testosterone Microcapsule Formulation Provides Uniform Eugonadal Levels of Testosterone for 10-11 Weeks in Hypogonadal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 74 (No. 1), pp. 75-83 (January 1992).	
,		95	ARVER, ET AL., "Improvement of Sexual Function in Testosterone Deficient Men Treated for 1 Year with a Permeation Enhanced Testosterone Transdermal System," Journal Of Urology, Vol. 155 (No. 5), pp. 1604-1608 (May 1996).	
		96	LIAO, "Androgen Action: Molecular Mechanism and Medical Application," J Formos Med. Assoc., Vol. 93 (No. 9), pp. 741-751 (September 1994).	1007
		97	CARLSTROM, ET AL., "Relationship Between Serum Testosterone and Sex Hormone-Binding Globulin in Adult Men with Intact or Absent Gonadal Function," International Journal Of Andrology (Vol. 13), pp. 67-73 (1990).	
		98	de LIGNIERES, ET AL., "Treatment of Male Hypogonadism by Topical Administration of Androgens," pp. 273-283 (1980).	3[
		99	DAVIDSON, ET AL., "Hormonal Changes and Sexual Function in Aging Men,"  Journal Of Clinical Endocrinology And Metabolism, Vol. 57 (No. 1), pp. 71-77 (1983).	CH CE
		100	VERMEULEN, ET AL., "Long-Term Transdermal Dihydrotestosterone Therapy: Effects on Pituitary Gonadal Axis and Plasma Lipoproteins," Maturitas, Vol. 7, pp. 281-287 (1985).	1600
5	19	101	MORRISON, "Androgens in the Elderly: Will Androgen Replacement Therapy Improve Mood, Cognition, and Quality of Life in Aging Men and Women," Psychopharmacology Bulletin, Vol. 33 (No. 2), pp. 293-296 (1997).	12900

Examiner Date Signature Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Substitute for form 1449B/PTO				Complete if Known		
INFORMATION DISCLOSURE				Application Number	09/703.753	
INFORMATION DISCLOSURE			CLUSURE	Filing Date	November 1, 2000	
STATEMENT BY APPLICANT				First Named Inventor	Robert E. Dudley	
OTATEMENT DI ATTEMANT		Group Art Unit	1617			
	(use as many she	ets a	s necessary)	Examiner Name	S. Jiang	
Sheet	8	of	21	Attorney Docket Number		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL' LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
99	102	JAFFE, ET AL., "Effect of 5-Alpha-Reductase Inhibition on Sex-Hormone-Binding Globulin in Elderly Men", Horm. Res., Vol. 41, pp. 215-217 (1994).	
	103	MORLEY, ET AL., "Androgen Deficiency in Aging Men: Role of Testosterone Replacement Therapy," J. Lab. Clin. Med., Vol. 135 (No. 5), pp. 370-378 (May 2000).	
	104	MARIN, ET AL., "Androgen Treatment of Middle-Aged, Obese Men: Effects on Metabolism, Muscle and Adipose Tissues," European Journal of Medicine, Vol. 1 (No. 6), pp. 329-336 (October 1992)	A
		WANG, ET AL., "Pharmacokinetics of Transdermal Testosterone Gel in Hypogonadal Men: Application of Gel at One Site Versus Four Sites: A General Clinical Research Center Study," The Journal Of Endocrinology And Metabolism, Vol. 85 (No. 3), pp. 964-969 (March 2000).	λ i
		KUHN, ET AL., "Percutaneous Androgen Treatment for Male Hypogonadism. Compared Efficacy of Testosterone and Dihydrotestosterone: Study of 40 Observations," Endocrinologie, Vol. 14 (No. 11), pp. 1031-1036 (1986) (English Translation).	6 7002
	107	HANDELSMAN, ET AL., "Pharmacokinetics and Pharmacodynamics of Testosterone Pelle Man," Journal Of Clinical Endocrinology And Metabolism, Vol. 70 (No. 1), pp. 216-222 (1990).	
		STUENKEL, ET AL., "Sublingual Administration of Testosterone-Hydroxypropyl-b-Cyclodextrin Inclusion Complex Simulates Episodic Androgen Release in Hypogonadal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 72 (No.5), pp. 1054-1059 (May 1991).	
		BHASIN, "Clinical Review 34 - Androgen Treatment of Hypogonadal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 74 (No. 6), pp. 1221-1225 (June 1992).	77-2
		SALEHIAN, ET AL., "Pharmacokinetics, Bioefficacy, and Safety of Sublingual Testosterone Cyclodextrin in Hypogonadal Men: Comparison to Testosterone Enanthate - A Clinical Research Center Study," Journal Of Clinical Endocrinology And Metabolism, Vol. 80 (No. 12), pp. 3567-3575 (1995).	) 
		MEIKLE, ET AL., "Pharmacokinetics and Metabolism of a Permeation-Enhanced Testosterone Transdermal System in Hypogonadal Men: Influence of Application Site - A Clinical Research Center Study," Journal Of Clinical Endocrinology And Metabolism, Vol. 81 (No. 5), pp. 1832-1840 (May 1996).	
599	/	WANG, ET AL., "Testosterone Replacement Therapy Improves Mood in Hypogonadal Men - A Clinical Research Center Study," Journal Of Clinical Endocrinology And Metabolism, Vol. 81 (No. 10), pp. 3578-3583 (1996).	

Examiner Signature	50	Date Considered	5/21/02
,		Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute fo	r form 1449B/PTO			Complete if Known		
INITOT	TANTA BAC	NIC	CLOCUDE	Application Number	09/703.753	
INFUR	KIVIA HON L	ノしこ	CLOSURE	Filing Date	November 1, 2000	
STATI	EMENT BY	' Δ	PPLICANT	First Named Inventor	Robert E. Dudlev	
• • • • • • • • • • • • • • • • • • •		,		Group Art Unit	1617	
	(use as many she	ets a	s necessary)	Examiner Name	S. Jiang	
Sheet	- 9	of	21	Attorney Docket Number	01736349	

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
299	113	WANG, ET AL., "Sublingual Testosterone Replacement Improves Muscle Mass and Strength, Decreases Bone Resorption, and Increases Bone Formation Markers in Hypogonadal Men - A Clinical Research Center Study," Journal Of Clinical Endocrinology And Metabolism, Vol. 81 (No. 10), pp. 3654-3662 (1996).		
	114	McCLELLAN, ET AL., "Transdermal Testosterone," Drugs, Vol. 55 (No. 2), pp. 253-258 (February 1998).		
	115	BHASIN, ET AL., "Therapeutic Perspective - Issues in Testosterone Replacement in Older Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 83 (No. 10), pp. 3435-3448 (1998).	CH CH	7. 17
	116	BEHRE, ET AL., "Intramuscular Injection of Testosterone Undecanoate for the Treatment of Male Hypogonadism: Phase I Studies," European Journal Of Endocrinology, Vol. 140, pp. 414-419 (1999).	NEE	1- E
	117	BEHRE, ET AL., "Long-Term Substitution Therapy of Hypogonadal Men with Transscrotal Testosterone Over 7-10 Years," Clinical Endocrinology, Vol. 50, pp. 629-635 (1999).	<b>8</b> 00/3	7007
-	118	PARKER, ET AL., "Experience with Transdermal Testosterone Replacement Therapy for Hypogonadal Men," Clinical Endocrinology, Vol. 50, pp. 57-62 (1999).	\$	
	119	SNYDER, ET AL., "Effect of Testosterone Treatment on Bone Mineral Density in Men Over 65 Years of Age," The Journal Of Clinical Endocrinology And Metabolism, Vol.84 (No. 6), pp. 1966-1972 (1999).		
÷	120	WANG, ET AL., "Comparative Pharmacokinetics of Three Doses of Percutaneous Dihydrotestosterone Gel in Healthy Elderly Men - A Clinical Research Center Study," Journal Of Clinical Endocrinology And Metabolism, Vol. 83 (No. 8), pp. 2749-2757 (August 1998).		
	121	LEIFKE, ET AL., "Effects of Testosterone Replacement Therapy on Cortical and Trabecular Bone Mineral Density, Vertebral Body Area and Paraspinal Muscle Area in Hypogonadal Men," European Journal of Endocrinology, Vol. 138, pp. 51-58 (1998).		CEN
59	122	BEHRE, ET AL., "Long-Term Effect of Testosterone Therapy on Bone Mineral Density in Hypogonadal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 82 (No. 8), pp. 2386-2390 (1997).		ECH CENTER 1600/2900
				8

Examiner	$\leq \alpha \gg$	Date	8/2-1/0
Signature		Considered	0/2002
	, ,		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not offation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next conformatication to applicant.

1 Applicant's unique citation designation number (optional). 
2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute fo	r form 1449B/PTO	•		Complete if Known		
INIEOE	A MOUTANA	NIC	CI OCUBE	Application Number	09/703.753	
HALOL	KIVIA HON L	JIC	CLOSURE	Filing Date	November 1, 2000	
STATI	EMENT BY	Δ	PPLICANT	First Named Inventor	Robert E. Dudlev	
•		•		Group Art Unit	1617	
	(use as many shee	ets a	s necessary)	Examiner Name	S. Jiang	
Sheet	10	of	21	Attorney Docket Number	01736349	

		NON PATENT LITERATURE DOCUMENTS	_
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т2
396	123	DAMASSA, ET AL., "Sex Hormone-Binding Globulin and Male Sexual Development," Neuroscience And Biobehavioral Reviews, Vol. 19 (No. 2), pp. 165-175 (1995).	
	124	MORLEY, ET AL., "Longitudinal Changes in Testosterone, Luteinizing Hormone, and Follicle-Stimulating Hormone in Healthy Older Men," Metabolism, Vol. 46 (No. 4), pp. 410-413 (April 1997).	
	125	CUNNINGHAM, ET AL., "Plasma Sex Hormone-Binding Globulin Levels Decrease During the Second Decade of Life Irrespective of Pubertal Status," Journal Of Clinical Endocrinology And Metabolism, Vol. 58 (No. 5), pp. 915-918 (1984).	TEC
	126	LEWIS, ET AL., "Serum 5a-Dihydrotestosterone and Testosterone Changes with Age in Man," ACTA Endocrinologica, Vol. 82, pp. 444-448 (1976).	
	127	HARDY, ET AL., "Endocrine Assessment of Impotence - Pitfalls of Measuring Serum Testosterone Without Sex-Hormone-Binding Globulin," Postgrad Medical Journal, Vol. 70, pp. 836-837 (1994).	TER 16
	128	DAVIDSON, ET AL., "Hormonal Replacement and Sexuality in Men," Clinics In Endocrinology And Metabolism, Vol. 11 (No. 3), pp. 599-623 (November 1982).	1600/290
		MANTZOROS, ET AL., "Contribution of Dihydrotestosterone to Male Sexual Behavior," British Medical Journal, Vol. 310, pp 1289-1291 (May 20, 1995).	0
		MOORADIAN, ET AL., "Biological Actions of Androgens," Endocrine Reviews, Vol. 8 (No. 1), pp 1-28 (1987).	7
	131	CUNNINGHAM, ET AL., "Testosterone Replacement Therapy and Sleep-Related Erections in Hypogonadal Men," Journal Of Clinical Endocrinology and Metabolism, Vol. 70 (No. 3), pp. 792-797 (1990).	
	132	SKAKKEBAEK, ET AL., "Androgen Replacement with Oral Testosterone Undecanoate in Hypogonadal Men: A Double Blind Controlled Study," Clinical Endocrinology, Vol. 14, pp. 49-61 (1981).	TED (600)
	)	38	
ブリ	133	de LIGNIERES, "Transdermal Dihydrotestosterone Treatment of Andropause," Annals Of Medicine, Vol. 25, pp. 235-241 (1993).	

Examiner Signature Date Considered 5/20/52				
			Data	1 4 1
Signature Considered >/ 2//32		$\sim 4$	Date	
Considered 1 1 Considered 9 1	Signature	$\mathcal{V}$	Considered	7 2010)
	Cloriature		Considered	<u> </u>

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Substitute fo	or form 1449B/PTO		•	Complete if Known		
		NIC	CLOCUDE	Application Number	09/703.753	
INFO	KIVIATION	JIS	CLOSURE	Filing Date	November 1, 2000	
STAT	FMFNT RY	' Δ	PPLICANT	First Named Inventor	Robert E. Dudley	
OIAI			III LIOAIII	Group Art Unit	1617	
	(use as many she	ets a	s necessary)	Examiner Name	S. Jiang	
Sheet	11	of	21	Attorney Docket Number	01736349	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
9	134	CHEMANA, ET AL., "Percutaneous Absorption of 5a-dihydrotestosterone in Man II. Percutaneous Administration of 5a-dihydrotestosterone in Hypogonadal Men with Idiopathic Haemochromatosis: Clinical, Metabolic and Hormonal Effectiveness," International Journal Of Andrology, Vol. 5, pp. 595-606 (1982).	
	135	McCLURE, ET AL., "Hypogonadal Impotence Treated by Transdermal Testosterone," Urology, Vol. XXXVII (No. 3), pp. 224-228 (March 1991).	
	136	GOOREN, "Androgen Levels and Sex Functions in Testosterone-Treated Hypogonada Men," Archives Of Sexual Behavior, Vol. 16 (No. 6), pp. 463-473 (1987).	1 -
	137	TSITOURAS, "Effects of Age on Testicular Function," Endocrinology And Metabolism Clinics, Vol. 16 (No. 4), pp.1045-1059 (December 1987).	i-
The same of the sa	138	ANDERSON, ET AL., "The Effects of Exogenous Testosterone on Sexuality and Mood of Normal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 75 (No. 6), pp.1503-1507 (1993)	000
	139	KNUSSMANN, ET AL., "Relations Between Sex Hormone Levels and Sexual Behavior in Men," Archives Of Sexual Behavior, Vol. 15 (No.5), pp. 429-5 (1986).	
	140	BANCROFT, "Endocrinology of Sexual Function," Clinics In Obstetrics And Gynecology, Vol. 7 (No. 2), pp. 253-281 (August 1980).	
	141	BAGATELL, ET AL., "Effects of Endogenous Testosterone and Estradiol on Sexual Behavior in Normal Young Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 78 (No. 3), pp. 711-716 (1994).	
	142	WEINBAUER, ET AL., "Pharmacokinetics and Pharmacodynamics of Testosterone Enanthate and Dihyrotestosterone Enanthate in Non-Human Primates," ACTA Endocrinologica (COPENH), Vol. 122 (No. 4), pp. 432-442 (1990).	APA
	143	"Sexual Dysfunction in the Male - Sexual Arousal Disorder," The Merck  Manual, Sixteenth Edition, Ch. 139, pp. 1575-1576 (1992).  JOCK ENHOVEL, ET Al., "Pharmacokinetics and Pharmacodynamics of	4002 9 T 8
5		JOCKENHOVEL, ET AL., "Pharmacokinetics and Pharmacodynamics of Subcutaneous Testosterone Implants in Hypogonadal Men," Clinical Endocrinology, Vol. 45, pp. 61-71 (1996).	2

Examiner Date Signature Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Substitute fo	or form 1449B/PTO			Complete if Known		
INICO	DAMATION		CL OCUDE	Application Number	09/703.753	
INFO	KIVIA HON I	DIS	CLOSURE	Filing Date	November 1, 2000	
STAT	EMENT BY	/ Δ	PPLICANT	First Named Inventor	Robert E. Dudley	
• • • • • • • • • • • • • • • • • • • •			I LIOAIII	Group Art Unit	1617	
	(use as many she	ets a	is necessary)	Examiner Name	S. Jiang	
Sheet	12	of	21	Attorney Docket Number		

			NON PATENT LITERATURE DOCUMENTS	
	aminer tials*	Cité No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
2	as	145	BEHRE, ET AL., "Testosterone Buciclate (20 Aet-1) in Hypogonadal Men: Pharmacokinetics and Pharmacodynamics of the New Long-Acting Androgen Ester," Journal Of Endocrinology And Metabolism," Vol. 75 (No. 5), pp. 1204-1210 (1992).	
Ĺ		146	SCHURMEYER, ET AL., "Comparative Pharmacokinetics of Testosterone Enanthate and Testosterone Cyclohexanecarboxylate as Assessed by Serum and Salivary Testosterone Levels in Normal Men," International Journal of Andrology, Vol. 7, pp. 181-187 (1984).	
		147	MAZER, ET AL., "Enhanced Transdermal Delivery of Testosterone: A New Physiological Approach for Androgen Replacement in Hypogonadal Men," Journal of Controlled Release, Vol. 19, pp. 347-361 (1992).	<b>&gt;</b> 00
	-	148	COFRANCESCO, Jr., ET AL., "Transdermal Testosterone Delivery System The Endocrinologist, Vol. 6 (No. 3), pp. 207-213 (1996).	o.
		149	BROCKS, ET AL., "Pharmacokinetics of Testosterone in Hypogonadal Men After Transdemal. Delivery: Influence of Dose," Journal of Clinical Pharmacology, Vol. 36, pp. 732-739 (1986).	2002
		150	ARVER, ET AL., "Long-Term Efficacy and Safety of a Permeation-Enhanced Testosterone Transdermal System in Hypogonadal Men," Clinical Endocrinology, Vol. 47, pp. 727-737 (1997).	
		151	MEIKLE, ET AL., "Androderm: A Permeation Enhanced Non-Scrotal Testosterone Transdermal System for the Treatment of Male Hypogonadism," Pharmacology, Biology, and Clinical Applications of Androgens, Vol. 43, pp. 449-457 (1996 Wiley-Liss, Inc.).	
		152	BALS-PRATSCH, ET AL., "Substitution Therapy of Hypogonadal Men with Transdermal Testosterone Over One Year," ACTA Endocrinologica (COPENH), Vol. 118, pp. 7-13 (1988)	
		153	CAREY, ET AL., "Transdermal Testosterone Treatment of Hypogonadal Memily The Journal of Urology, Vol. 140, pp. 76-79, (July 1988).	
		<b>1/</b> 54	CUNNINGHAM, ET AL., "Testosterone Transdermal Delivery System,"  Pharmacology, Biology, and Clinical Applications of Androgens, Vol. 42, pp. 437-447 (1996 Wiley-Liss, Inc).	APR 1 6
S			Product Information - Testoderm TTS, Physicians' Desk Reference, Alza pp 517-520.	2002

Examiner		Date 5/2	1/0
Signature I	<i>Y</i> ' <del>3</del> /)	Considered	

RECEIVED

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449B/PTO Application Number 09/703.753 INFORMATION DISCLOSURE Filing Date November 1, 2000 STATEMENT BY APPLICANT First Named Inventor Robert E. Dudley Group Art Unit 1617 S. Jiang (use as many sheets as necessary) **Examiner Name** 

Attorney Docket Number | 01736349

1:3

Sheet

Examiner

of

		NON PATENT LITERATURE DOCUMENTS	
Examiner Cit Initials* No		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
99 (	156	YU, ET AL., "Testosterone Pharmacokinetics after Application of an Investigational Transdermal System in Hypogonadal Men," Journal of Clinical Pharmacology, Vol. 37, pp. 1139-1145 (1997).	
	157	YU, ET AL., "Transdermal Testosterone Administration in Hypogonadal Men: Comparison of Pharmacokinetics at Different Sites of Application and at the First and Fifth Days of Application," Journal of Clinical Pharmacology, Vol. 37, pp. 1129-1138 (1997).	
	158	WALTERS, "Penetration Enhancers and Their Use in Transdermal Therapeut Systems," pp. 202-227 (1990).	II.
	159	GENNARO, "Remington: The Science and Practice of Pharmacy, 20th Edition Chapter 44, pp. 842-843 (2000).	7 7 7
	160	JARKANDER-ROLFF, ET AL., "Transdermal Application of A Testosterone 68 Gel - A Pharmacokinetic Study."	2002
	161	TIRASSA, ET AL., "High-Dose Anabolic Androgenic Steroids Modulate Concentrations of New Growth Factor and Expression of its Low Affinity Receptor (p75-NGFr) in Male Rat Brain," Sournal of Neuroscience Research, Vol. 47 (No. 2), pp. 198-207 (January 15, 1997).	
	162	VELDHUIS, ET AL., "Muting of Androgen Negative Feedback Unveils Impoverished Gonadotropin-Releasing Hormone/Luteinizing Hormone Secretory Reactivity in Healthy Older Men," The Journal of Clinical Endocrinology & Metabolism, Vol. 86 (No. 2), pp. 529-535. (2001)	l
	163	MILLER, ET AL., "Androgen Deficiency in Women with Hypopituitarism," The Journal of Clinical Endocrinology & Metabolism, Vol. 86 (No.2), pp. 561-567 (2001).	
	164	KAO, ET AL., "Skin Absorption and Cutaneous First Pass Metabolism of Topical Steroids: in vitro Studies with Mouse Skin in Organ Culture," Journal of Pharmacology and Experimental Therapeutics, Vol. 241 (No. 2), pp. 482-487 (May 1987).	
	1,65	FINDLAY, ET AL., "Treatment of Primary Hypogonadism in Men by the Transdermal Administration of Testosterone," Journal Of Clinical Endocrinology And Metabolism, Vol. 68 (No. 2), pp. 369-373 (February 1989).	
59		ERNESTI, ET AL., "Absorption and Metabolism of Topically Applied Testosterone in an Organotypic Skin Culture," Skin Pharmacology, Vol. 5 (No. 3), pp. 146-153 (1992).	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Date Considered

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

ubstitute fo	or form 1449B/PTO			Complete if Known			
NEOE	RMATION D	Ne/	CLOCUDE	Application Number	09/703.753		
NFU	KINIA HON L	JIOU	PLOSUKE	Filing Date	November 1, 2000		
TAT	EMENT BY	ΔΕ	PPLICANT	First Named Inventor	Robert E. Dudley		
,		,	LIOAII	Group Art Unit	1617		
	(use as many shee	ets as	necessary)	Examiner Name	S. Jiang		
Sheet	14	of	21	Attorney Docket Number	01736340		

	NON PATENT LITERATURE DOCUMENTS							
	Examiner nitials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>				
2		167	CHOI, ET AL., "Transdermal Dihydrotestosterone Therapy and its Effects on Patients with Microphallus," Journal Of Urology, Vol. 150 (No. 2) (Part 2), pp. 657-660 (August 1993).					
		168	Testosterone, Chapters 1, 6-16 (1999).					
		169	TSAI, ET AL., "Metabolic Approaches to Enhance Transdermal Drug Delivery. 1. Effect of Lipid Synthesis Inhibitors," Journal of Pharmaceutical Sciences, Vol. 85 (No. 6), pp. 643-648 (June 1996).					
		170	MEIKLE, ET AL., "Familial Effects on Plasma Sex-Steroid Content in Man: Testosterone, Estradal and Sex-Hormone-Binding Globulin," Metabolism, Vol. 31 (No. 1), pp. 6-9 (January 1982).	,				
		171	SHANBHAG, ET AL., "The Temperature Dependence of the Binding of 5 Alpha-Dihydrotestosterone, Testosterone and Estradiol to the Sex Hormone Globulin (SHBG) of Human Plasma," J. Steroid Biochem., Vol. 24 (No. 2), pp. 549-555 (February 1986).	1 14				
		172	BELGOROSKY, ET AL., "Changes in Serum Sex Hormone-Binding Globulin and in Serum Non-Sex Hormone-Binding Globulin-Bound Testosterone During Prepuberty in Boys," J. Sterois Biochem., Vol. 27 (Nos. 1-3), pp. 291-295 (1987).	0 (00L				
		173	KORENMAN, ET AL., "Androgen Therapy of Hypogonadal Men with Transscrotal Testoster Systems," American Journal Of Medicine, Vol. 83 (No. 3), pp. 471-478 (September 1987).					
<u>.</u>		- 1	MITCHELL, ET AL., "Age Related Changes in the Pituitary-Testicular Axis in Normal Men; Lower Serum Testosterone Results from Decreased Bioactive LH Drive," Clinical Endocrinology (OXF), Vol. 42 (No. 5), pp. 501-507 (May 1995).					
		175	NANKIN, ET AL., "Decreased Bioavailable Testosterone In Aging Normal and Impotent Men,"  Journal Of Clinical Endocrinology And Metabolism, Vol. 63 (No. 6), pp. 1418-1420 (December 1986).					
			TENOVER, ET AL., "The Effects of Aging in Normal Men on Bioavailable Testosterone and Luteinizing Hormone Secretion: Response to Clominhene	ddy				
/	90	- 1	Citrate," Journal Of Clinical Endocrinology And Metabolism, Vol. 65 (No. 6) pp. 1118-1126 (December 1987).  WINTERS, ET AL., "The Gonadotropin-Suppressive Activity of Androgen is Increased in Elderly Men," Metabolism, Vol. 33 (No. 11), pp. 1052-1059 (November 1984).	1 6 2002				
_								

Examiner Date Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Substitute for form 1449B/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

15

(use as many sheets as necessary)

21

Complete if Known				
Application Number	09/703.753			
Filing Date	November 1, 2000			
First Named Inventor	Robert E. Dudley			
Group Art Unit	1617			
Examiner Name	S. Jiang			
Attorney Docket Number				

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
50	) 178	MEIKLE, ET AL., "Enhanced Transdermal Delivery of Testosterone Across Nonscrotal Skin Produces Physiological Concentrations of Testosterone and Its Metabolites in Hypogonadal Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 74 (No. 3), pp. 623-628 (March 1992).	
	179	WINTERS, ET AL., "Serum LH Concentrations in Hypogonadal Men During Transdermal Testosterone Replacement Through Scrotal Skin: Further Evidence That Ageing Enhances Testosterone Negative Feedback. The Testoderm Study Group," Clinical Endocrinology (OXF), Vol. 47 (No. 3), pp. 317-322 (September 1997).	
	180	BOYLE, ET AL., "Serum Testosterone Measurements," American Journal Of Clinical Pathology, Vol. 81 (No. 6), pp. 754-761 (June 1984).	ECH (
	181	HOLOWNIA, ET AL., "A Clinical Evaluation of A Direct Radioimmunoassay of Testosterone," Clinical Chimica Acta, Vol. 214 (No. 1), pp. 31-43 (January 31, 1993).	CENTER
,	182	BELGOROSKY, ET AL., "Progressive Decrease in Serum Sex Hormone-Binding Globulin from Infancy to Late Prepuberty in Boys," Journal Of Clinical Endocrinology And Metabolism, Vol. 63 (No. 2), pp. 510-512 (August 1986).	
	183	VALERO-POLITI, ET AL., "Daily Rhythmic and Non-Rhythmic Variations of Follitropin, Lutropin, Testosterone, and Sex-Hormone-Binding Globulin in Men," Eur. J. Clin. Chem. Clin. Biochem., Vol. 34 (No. 6), pp. 455-462 (June 1996).	600 2900
	184	VALERO-POLITI, ET AL., "Annual Rhythmic Variations of Follitropin, Lutropin, Testosterone and Sex-Hormone-Binding Globulin in Men," Clinica Chimica Acta, Vol. 271 (No. 1), pp. 57-71 (March 9, 1998).	
	185	LONGCOPE, ET AL., "Androgens, Estrogens, and Sex Hormone-Binding Globulin in Middle-Aged Men," Journal Of Clinical Endocrinology And Metabolism, Vol. 71 (No. 6), pp. 1442-1446 (December 1990).	
	186	BELGOROSKY, ET AL., "Dynamics of SHBG Response to Testosterone. Implications Upon the Immediate Biological Effect of Sex Hormones," J. Steroid Biochem., Vol. 18 (No. 6), pp. 783-787 (1983).	
	187	LEWIS, ET AL., "Proceedings: Age-Related Changes in Serum 5aplha-dihydrotestosterone and Testosterone in Normal Men," Journal Of Endocrinology, Vol. 67 (No. 2), pg. 15P (November 1975).	1 6 7 BAN
89		PIRKE, ET AL., "Age Related Changes and Interrelationships Between Plasmer Testosterone, Oestradiol and Testosterone-Binding Globulin in Normal Adult Males," ACTA Endocrinologica (COPENH), Vol. 74 (No. 4), pp. 792-800 (December 1973).	2002

Examiner Date Signature Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

	1.10	"COLOGO 1	10001
Approved for use through	10/31/2002.	OMB 065	1-0031
rademark Office: U.S. DEF	PARTMENT	OF COMM	IERCE
antication of information			

Substitute fo	r form 1449B/PTO			Complete if Known		
		210	CLOCUBE	Application Number	09/703.753	
INFOR	KIVIATION	JIO	CLOSURE	Filing Date	November 1, 2000	
STATI	EMENT BY	′ Δ	PPLICANT	First Named Inventor	Robert E. Dudlev	
OIA			LIOAITI	Group Art Unit	1617	
	(use as many she	ets a	s necessary)	Examiner Name	S. Jiang	
Sheet	16	of	21	Attorney Docket Number	01736349	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
At I	189	MASTERS, ET AL., "Investigation of Sex-Hormone Binding Globulin Interference in Direct Radioimmunoassays for Testosterone and Estradiol," Clinical Chemistry, Vol. 35 (No. 6), pp. 979-984 (June 1989).	IE 우
	190	WANG, ET AL., "Salivary Testosterone in Men: Further Evidence of a Direct Correlation with Free Serum Testosterone," Journal Of Clinical Endocrinology And Metabolism, Vol. 53 (No. 5), pp. 1021-1024 (November 1981).	CENT
	191	ZMUDA, ET AL., "Exercise Increases Serum Testosterone and Sex Hormone-Binding Globulin Levels in Older Men," Metabolism, Vol. 45 (No. 8), pp. 935-939 (August 1996).	ER 160
	192	GAIDANO, ET AL., "Dynamics of the Binding Capacity of Plasma Sex Hormone Binding Globulin (SHBG) for Testosterone and Dihydrotestosterone During Puberty," Clinical Chimica Acta, Vol. 100 (No. 2), pp. 91-97 (January 15, 1980).	1600/2900
	193	Definition of Isopropyl Myristate (5103), The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals, Eleventh Edition, p. 821 (1989).	
	194	GENNARO, ET AL., Remington's Pharmaceutical Sciences, Eighteenth Edition, pp. 1305, 1314-1315 (1990).	HO
	195	LANGTRY, ET AL., "Sildenafil - A Review of its Use in Erectile Dysfunction," Drugs, Vol. 57 (No. 6), pp. 967-989 (1999).	CENT
	196	MORELAND, ET AL., "Sildenafil, A Novel Inhibitor of Phosphodiesterase Type 5 In Human Corpus Cavernosum Smooth Muscle Cells," Life Sciences, Vol. 62 (No. 20) pp. PL309-318 (1998).	ER 160
	197	FAHRNER, ET AL., "Effects of Endurance Exercise on Free Testosterone Concentration and the Binding Affinity of Sex Hormone Binding Globulin (SHBG)," International Journal Of Sports Medicine, Vol. 19 (No. 1), pp. 12-15 (January 1998). [Abstract]	0/2900
	1,98	BARTSCH, "Interrelationships Between Sex Hormone-Binding Globulin and Testosterone, 5 alpha-Dihydrotestosterone and Oestradiol-17 beta in Blood of Normal Men," Maturitas, Vol. 2 (No. 2), pp. 109-118 (July 1980). [Abstract]	
9	199	WANG, ET AL., "Effects of Transdermal Testosterone Gel on Bone Turnover Markers and Bone Mineral Density in Hypogonadal Men," Clinical Endocrinology, Vol. 54, pp. 1-13 (2001).	

ĺ	Examiner Signature	SAY	Date Considered	5/21/5
•	Sidilatule		T Collsidered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449B/PTO 09/703.753 Application Number INFORMATION DISCLOSURE November 1, 2000 Filing Date STATEMENT BY APPLICANT **First Named Inventor** Robert E. Dudley Group Art Unit 1617 (use as many sheets as necessary) **Examiner Name** S. Jiang 17 Attorney Docket Number Sheet of 01736349

NON PATENT LITERATURE DOCUMENTS								
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>					
697	200	GOOREN, "A Ten-Year Safety Study of the Oral Androgen Testosterone Undecanoate," J. Androl., Vol. 15 (No. 3), pp. 212-215 (May-June 1994). [Abstract]						
	201	MAZER, "New Clinical Applications of Transdermal Testosterone Delivery in Men and Women," J. Controlled Release, Vol. 65 (No. 1-2), pp. 303-315 (March 1, 2000). [Abstract]						
40	202	ITOH, ET AL., "The Assessment of Bioavailable Androgen Levels from the Serum Free Testosterone Level, "Nippon Naibunpi Gakkai Zasshi, Vol. 67 (No. 1), pp. 23-32 (January 20, 1991). [Abstract]	150					
	<del>20</del> 3	Male Hormone Patch Approved, Nupharm, http://www.nupharm-com/malehorm-htm:	CEN					
	204	"SmithKline Beecham's New 5 mg Androderm Testosterone Transdermal System Now Available," International Association of Physicians in AIDS Care, http://www.iapac.org/clinmgt/compnews/sb061297:html*(June 12, 1997)	TER 16					
٠.	205	"Impotence Treatments," Impotence World Association, http://www.impotenceworld.org/treatment.htm (2000).	CENTER 18001 290					
	206	"Andro-Gel," Netrition, http://www.netrition.com/andro_gel_page.html (1997-1998).						
	207	"Cellegy Pharmaceuticals Market Opportunities," CELLEGY PHARMACEUTICALS, INC., http://www.cellegy.com/corp/market-html-(1997)						
		"Prospectus - Cellegy Pharmaceuticals, Inc.," OPPENHEIMER & CO., pp. 1-421-28 (1997).	APF					
		TER	. j 6					
	209	The Testosterone Source, http://www.testosteronesource.com-(1998).	2002					
		BONNEY, "Hormone Replacement Therapy for Men," American Clinical Laboratory, http://iscpubs.com/pubs/acl/acl/197-html						
		(November/December1997).						

Examiner Signature	· 527	Date Considered	Mor
Sidilatule I		I Considered	<u> </u>
			7/

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Substitute for	r form 1449B/PTO			Complete if Known		
-		nie	CLOCUDE	Application Number	09/703.753	
INFOR	CIVIATION	פוע	CLOSURE	Filing Date	November 1, 2000	
STATE	MENT BY	/ Δ	PPLICANT	First Named Inventor	Robert E. Dudlev	
0.7			· · LIOAII	Group Art Unit	1617	
	(use as many she	ets a	s necessary)	Examiner Name	S. Jiang	
Sheet	18	of	21	Attorney Docket Number	01736349	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	211	Andropausal, Los Gatos Longevity Institute,  http://www.antiaging.com/andropause.html (1998).	
	<del>212</del>	TestoCreme - A Natural Transdermal Testosterone Replacement Therapy, www.testocreme.com.	APR
G9N	213	WANG, ET AL., "Pharmacokinetics Of Transdermal Testosterone Gel in Hypogodiada Men," ENDO '98 SUBMISSION PROGRAM, 1998N ABSTRACT FORM.	6 2
	214	SWERDLOFF, ETAL., "Long Term Pharmacokinetics of Transdermal Testosterone Gel Versus Testosterone Patch in Hypogonadal Men," 2347 Male Reproductive Poster Session, Board 578 (June 22, 2000).	002
	215	WANG, ET AL., "Effects of Transdermal Testosterone Gel on Bone Turnover Markers and Bone Mineral Density in Hypogonadal Men," 2348 Male Reproductive Poster Session, Board 579 (June 22, 2000).	
	216	WANG, ET AL, "Transdermal Testosterone Gel Improves Sexual Function, Mood, Muscle Strength, and Body Composition Parameters in Hypogonadal Men," Basic Science: Reproduction-Gonadal Control (Male), Male Reproduction Oral Session, No. 1360 (June 24, 2000).	
	217	"Unimed Pharmaceuticals' Androgel Shows Solid Promise for Men," Fertility Industry News, www. INCIID.com (August 19, 1998).	
SA	218	RIGGS, "Unimed Begins Pivotal Clinical Trial For Innovative Testosterone Gel," Unimed News Release, pp. 1-2 (March 31, 1997).	CHC
	219	Androgel 1% (testosterone gel) CHL; www-Androgel-com, pp. 1-2.	NTER
		VERGEL, "Anabolic Steroids: A Practical Guide," CRIA Update, Vol. 7 (No. 3) (Summer 1998).	1600/2900
		MOONEY, "Frequencey of Administration - Testosterone & Nandrolone," Vol. 1 (No. 4), www:medibolics:com (Downloaded-10/8/98):	

Examiner Signature	>4X	Date 5/2 1/02
· · · · · · · · · · · · · · · · · ·		, ,

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Substitute fo	or form 1449B/PTO			Complete if Known		
		אוכ	CLOCUDE	Application Number	09/703.753	
INFOR	KIVIATION	JIS	CLOSURE	Filing Date	November 1, 2000	
STAT	EMENT RY	' Δ	PPLICANT	First Named Inventor	Robert E. Dudlev	
OIAII			II LIOAII	Group Art Unit	1617	
	(use as many she	ets e	s necessary)	Examiner Name	S. Jiang	
Sheet	19	of	21	Attorney Docket Number	01736349	3

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	ז
	222	Anabolic Steroids, Project Inform, Anabolic Steroids Quick Sheet (December 1997).	_
	223	"Anabolic Steroid Boosts Weight," GMHC Treatment Issues, Vol. 10, No. 9 (September 1996).	
Managa program at 19		Anabolic Steroids, Project-Inform Hotline Handout, www.projinf.org. (Downloaded 10/8/98).	
-	225	Anabolic Steroids - A Simple Facts Sheet From The Network, www.network/simple/steroids (Downloaded 10/27/98).	NIET.
المعاص المعادية المعا	226	USP Drug Information - Anabolic Steroids (Systemic), MayoClinic, www.mayohealth.org (Downloaded 10/8/98).	7/1/10
سيستعدد سد	227	MOONEY, "Anabolic Steroids For AIDS Therapy: Differences Between Analogs," No. 1, www.digiweb.com. (July 1998).	2
transmi eë 1.	228	Testocreme - No Shots, No Pills, No Patches, www.testocreme.com (Downloaded 7/10/00).	3000
	229	"ENDO 99: Testosterone Patch Effective For Diminished Sexual Function in Surgically Menopausal Women," www.pslgroup.com (June 15, 1999).	W70.
ी <i>िकाम मुख्या</i> संदर्भ		"Data Supports Safety of Estratest For Men," Doctor's Guide, www.pslgroup.com (March 9, 1998).	
	231	"Testosterone's Role in the Female Sex Drive," USA Today News, www.usatoday.com (April 8, 1996).	
		00/290	1
		"Alternative to Viagra For Women?," www.mdhealthline.com (Downloaded	<u>4</u>

Date Examiner Signature Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute fo	r form 1449B/PTO			Complete if Known		
		SIC	CLOCUDE	Application Number	09/703.753	
INFOR	KIVIATION L	כוע	CLOSURE	Filing Date	November 1, 2000	
STATI	EMENT RY	΄ Δ	PPLICANT	First Named Inventor	Robert E. Dudley	
OIAI.		_	LIOAITI	Group Art Unit	1617	
	(use as many shee	ets a	s necessary)	Examiner Name	S. Jiang	
Sheet	- 20	of	21	Attorney Docket Number	01736349	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
AT	233	"Never Too Buff," Time Europe, www.time.com, Vol. 155 (No. 16) (April 24, 2000).	5 5 5
	234	Gefael, Graeme's Testosterone-Page, www.voyager.co.nz (5/12/00).	מחדה
-	235	Estrogel; www:netdoktor:dk/medicin/Fakta/Estrogel-(Downloaded-6/26/01).	22.
	236	La Sexualite, L'Androgel, Le Gel Miracle,  www.aci-multimedia:net/feminin/androgel-(Downloaded-5/9/01):	, -
	237	Stehli, et al., Info, Info Androgel, www.mageos.ifrance.com/nade38/androgel (Downloaded-5/9/01).	PR
	238	CHERRIER, ET AL., "T-Gel Study: Cognitive Effects of Exogenous Testosterone Manipulation in Hypogonadal Men" (6/7/99).	0 L 0 0
	239	"Bentley Pharmaceuticals Annouces Research and Licensing Agreements For Intranasal Pain Management-and-Fopical-Hormone-Replacement Therapy," www.bentleypharm.com (downloaded 11/17/01).	
e i i ka <del>amana</del> s	240	"Testosterone Gel May Help Men with Low Sex Drive," WRAL ONLINE, http://www.wral-tv.com/features/healthteam/1997/0814-tgel/(August 14, 1997).	
The state of the s	241	"Testocreme Transdermal Testosterone Is New," Preventive Medicine Clinic Of Monterey, http://www.wellnessmd.com/testo.html.	150
gamenta e e e e e e e e e e e e e e e e e e e	242	"SEPA Testosterone Transdermal Gel-Receives-Application-by-FDA," Doctor's Guide Global Edition, http://pslgroup.com/dg/123aa.htm (January 15, 1997).	GETINEO I
5	243	http://www.mchm.com/press/pr24.asp (October 21, 1999).	

Date Examiner Signature Considered \*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute fo	r form 1449B/PTO			Complete if Known		
INIEOE	IAOIT A BAC	DIC	CLOSURE	Application Number	09/703.753	
INFOR	CIVIA I I CIV	פוט	CLOSUKE	Filing Date	November 1, 2000	
STATI	EMENT BY	YA	PPLICANT	First Named Inventor	Robert E. Dudley	
• • • • • • • • • • • • • • • • • • • •			2.0/	Group Art Unit	1617	
	(use as many sh	ets a	s necessary)	Examiner Name	S. Jiang	
Sheet	21	of	21	Attorney Docket Number	01736615	

		NON PATENT LITERATURE DOCUMENTS	1	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	ECH (	ĩΑ
	244		ENTE	PR 1
	245	MANOS, "FDA Approves Gel to Treat Low Testosterone Levels," www.testocreme.com (Downloaded 5/09/01).	1600/	3 2002
	246	"Unimed Pharmaceuticals' Androgel Shows Solid Promise for Men," Fertility Industry News, www.INCIID.com (August 19, 1998).	2900	
591	247	LACAYO, "Are You Man Enough?," Time Europe, www.Time.com, Vol. 15 No. 16 (April 24, 2000).	55,	
	248	"MacroChem Accelerates Development of Top For Impotence," www.pslgroup.com (April 10, 1997).	TEG	į
SI)	249	BRADLEY, "Potential Expanded Indications for Androgen Treatment," The Endocrine Society, No. 166 (ENDO 2000).	H CEN	APK
		WANG, ET AL., "New Androgen Formulations," The Endocrine Society, No. 167 (ENDO 2000).	.ER 16	0 کر
	251	WANG, ET AL., "Transdermal Testosterone Gel Improves Sexual Function, Mood, Muscle Strand Body Composition Parameters in Hypogonadal Men," The Endocrine Society, No. 1360 (El 2000).	2069	70
	252	WITTERT, ET AL., "Androgen Deficiency in Aging Men," The Endocrine Society, No. 1626 (ENDO 2000).		•
	253	BRILL, ET AL., "Single and Joint Impact of One-Month of Transdermal Testosterone (T) and/or Recombinant Human Growth Hormone (rhGH) Supplementation on Body Composition, Strengt Balance, Function and Muscle IGF-I and Androgen Gene Expression in Healthy Older Men: A Prospective Randomized Double-Blind Crossover," The Endocrine Society, No. 1647 (ENDO 2)	հ, H C	
			TER 1	. !
			600/29	/ [
Examine: Signature		Date Considered 5/21/6	8 7	_

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.